0001360214 2021-01-01 2021-03-31 0001360214 HROW:CommonStock0.001ParValuePerShareMember 2021-01-01 2021-03-31 0001360214 HROW:Sec8.625SeniorNotesDue2026Member 2021-01-01 2021-03-31 0001360214 2021-05-10 0001360214 2021-03-31 0001360214 2020-12-31 0001360214 HROW:SurfaceOphthalmicsMember 2021-03-31 0001360214 HROW:SurfaceOphthalmicsMember 2020-12-31 0001360214 HROW:MeltPharmaceuticalsMember 2021-03-31 0001360214 HROW:MeltPharmaceuticalsMember 2020-12-31 0001360214 2020-01-01 2020-03-31 0001360214 HROW:ProductSalesNetMember 2021-01-01 2021-03-31 0001360214 HROW:ProductSalesNetMember 2020-01-01 2020-03-31 0001360214 HROW:OtherRevenuesMember 2021-01-01 2021-03-31 0001360214 HROW:OtherRevenuesMember 2020-01-01 2020-03-31 0001360214 HROW:MeltPharmaceuticalsMember 2021-01-01 2021-03-31 0001360214 HROW:MeltPharmaceuticalsMember 2020-01-01 2020-03-31 0001360214 HROW:SurfaceOphthalmicsMember 2021-01-01 2021-03-31 0001360214 HROW:SurfaceOphthalmicsMember 2020-01-01 2020-03-31 0001360214 HROW:EtonPharmaceuticalsMember 2021-01-01 2021-03-31 0001360214 HROW:EtonPharmaceuticalsMember 2020-01-01 2020-03-31 0001360214 us-gaap:CommonStockMember 2019-12-31 0001360214 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001360214 us-gaap:RetainedEarningsMember 2019-12-31 0001360214 us-gaap:ParentMember 2019-12-31 0001360214 us-gaap:NoncontrollingInterestMember 2019-12-31 0001360214 2019-12-31 0001360214 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001360214 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001360214 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001360214 us-gaap:ParentMember 2020-01-01 2020-03-31 0001360214 us-gaap:NoncontrollingInterestMember 2020-01-01 2020-03-31 0001360214 us-gaap:CommonStockMember 2020-03-31 0001360214 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001360214 us-gaap:RetainedEarningsMember 2020-03-31 0001360214 us-gaap:ParentMember 2020-03-31 0001360214 us-gaap:NoncontrollingInterestMember 2020-03-31 0001360214 2020-03-31 0001360214 us-gaap:CommonStockMember 2020-12-31 0001360214 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001360214 us-gaap:RetainedEarningsMember 2020-12-31 0001360214 us-gaap:ParentMember 2020-12-31 0001360214 us-gaap:NoncontrollingInterestMember 2020-12-31 0001360214 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001360214 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001360214 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001360214 us-gaap:ParentMember 2021-01-01 2021-03-31 0001360214 us-gaap:NoncontrollingInterestMember 2021-01-01 2021-03-31 0001360214 us-gaap:CommonStockMember 2021-03-31 0001360214 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001360214 us-gaap:RetainedEarningsMember 2021-03-31 0001360214 us-gaap:ParentMember 2021-03-31 0001360214 us-gaap:NoncontrollingInterestMember 2021-03-31 0001360214 us-gaap:WarrantMember 2021-01-01 2021-03-31 0001360214 HROW:StockOptionsMember 2021-01-01 2021-03-31 0001360214 HROW:EtonPharmaceuticalsIncMember 2021-03-31 0001360214 HROW:EtonPharmaceuticalsIncMember 2021-01-01 2021-03-31 0001360214 HROW:EtonPharmaceuticalsIncMember 2020-01-01 2020-03-31 0001360214 us-gaap:SubsequentEventMember HROW:EtonPharmaceuticalsIncMember 2021-04-01 2021-04-30 0001360214 HROW:MeltPharmaceuticalsIncMember 2021-03-31 0001360214 HROW:MeltPharmaceuticalsIncMember 2021-01-01 2021-03-31 0001360214 HROW:MeltPharmaceuticalsIncMember 2020-01-01 2020-03-31 0001360214 HROW:MeltPharmaceuticalsIncMember 2020-12-31 0001360214 HROW:SurfacePharmaceuticalsIncMember 2021-03-31 0001360214 HROW:SurfacePharmaceuticalsIncMember 2021-01-01 2021-03-31 0001360214 HROW:SurfacePharmaceuticalsIncMember 2020-01-01 2020-03-31 0001360214 HROW:SurfacePharmaceuticalsIncMember 2020-12-31 0001360214 HROW:CommissionsMember 2021-01-01 2021-03-31 0001360214 HROW:CommissionsMember 2020-01-01 2020-03-31 0001360214 us-gaap:LicenseMember 2021-01-01 2021-03-31 0001360214 us-gaap:LicenseMember 2020-01-01 2020-03-31 0001360214 HROW:ManagementServicesAgreementMember HROW:MeltPharmaceuticalsIncMember 2019-02-01 2019-02-28 0001360214 HROW:ManagementServicesAgreementMember HROW:MeltPharmaceuticalsIncMember 2021-03-31 0001360214 HROW:ManagementServicesAgreementMember HROW:MeltPharmaceuticalsIncMember 2020-12-31 0001360214 HROW:DrLindstromMember HROW:SurfacePharmaceuticalsIncMember 2020-01-01 2020-12-31 0001360214 srt:MinimumMember us-gaap:PatentsMember 2021-01-01 2021-03-31 0001360214 srt:MaximumMember us-gaap:PatentsMember 2021-01-01 2021-03-31 0001360214 us-gaap:PatentsMember 2021-03-31 0001360214 HROW:LicensesMember 2021-01-01 2021-03-31 0001360214 HROW:LicensesMember 2021-03-31 0001360214 us-gaap:TrademarksMember 2021-01-01 2021-03-31 0001360214 us-gaap:TrademarksMember 2021-03-31 0001360214 srt:MinimumMember us-gaap:CustomerRelationshipsMember 2021-01-01 2021-03-31 0001360214 srt:MaximumMember us-gaap:CustomerRelationshipsMember 2021-01-01 2021-03-31 0001360214 us-gaap:CustomerRelationshipsMember 2021-03-31 0001360214 us-gaap:TradeNamesMember 2021-01-01 2021-03-31 0001360214 us-gaap:TradeNamesMember 2021-03-31 0001360214 srt:MinimumMember HROW:NonCompetitionClauseMember 2021-01-01 2021-03-31 0001360214 srt:MaximumMember HROW:NonCompetitionClauseMember 2021-01-01 2021-03-31 0001360214 HROW:NonCompetitionClauseMember 2021-03-31 0001360214 HROW:StatePharmacyLicensesMember 2021-01-01 2021-03-31 0001360214 HROW:StatePharmacyLicensesMember 2021-03-31 0001360214 us-gaap:PatentsMember 2021-01-01 2021-03-31 0001360214 us-gaap:PatentsMember 2020-01-01 2020-03-31 0001360214 HROW:LicensesMember 2020-01-01 2020-03-31 0001360214 us-gaap:CustomerRelationshipsMember 2021-01-01 2021-03-31 0001360214 us-gaap:CustomerRelationshipsMember 2020-01-01 2020-03-31 0001360214 us-gaap:TradeNamesMember 2020-01-01 2020-03-31 0001360214 HROW:StatePharmacyLicensesMember 2020-01-01 2020-03-31 0001360214 HROW:TermLoanAndSecurityAgreementMember HROW:SWKFundingLLCMember 2017-07-31 0001360214 srt:MinimumMember HROW:TermLoanAndSecurityAgreementMember us-gaap:LondonInterbankOfferedRateLIBORMember HROW:SWKFundingLLCMember 2017-07-31 0001360214 HROW:TermLoanAndSecurityAgreementMember us-gaap:BaseRateMember HROW:SWKFundingLLCMember 2017-07-31 0001360214 HROW:TermLoanAndSecurityAgreementMember HROW:SWKFundingLLCMember 2017-07-01 2017-07-31 0001360214 us-gaap:SubsequentEventMember 2021-05-11 0001360214 HROW:SWKSecondAmendmentMember 2021-01-01 2021-03-31 0001360214 HROW:SWKSecondAmendmentMember 2020-01-01 2020-03-31 0001360214 HROW:BusinessLoanAgreementMember 2020-04-30 0001360214 HROW:SanDiegoMember 2021-03-31 0001360214 HROW:SanDiegoMember 2021-01-01 2021-03-31 0001360214 HROW:LedgewoodMember 2021-03-31 0001360214 HROW:LedgewoodMember 2021-01-01 2021-03-31 0001360214 HROW:LedgewoodMember HROW:AdditionalSquareFootageOfLeaseMember 2021-03-31 0001360214 HROW:NashvilleMember 2021-03-31 0001360214 HROW:NashvilleMember 2021-01-01 2021-03-31 0001360214 us-gaap:CommonStockMember 2021-03-01 2021-03-31 0001360214 us-gaap:CommonStockMember 2020-03-01 2020-03-31 0001360214 HROW:MarkLBaumMember us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001360214 HROW:MarkLBaumMember us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-03-31 0001360214 HROW:AndrewRBollMember us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001360214 HROW:AndrewRBollMember us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-03-31 0001360214 srt:DirectorMember us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-03-31 0001360214 HROW:SeriesCCumulativePreferredStockMember us-gaap:SubsequentEventMember 2021-05-11 0001360214 HROW:SeriesCCumulativePreferredStockMember us-gaap:SubsequentEventMember 2021-04-01 2021-05-11 0001360214 HROW:TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember 2021-03-31 0001360214 HROW:StockOptionPlanOneMember 2020-12-31 0001360214 HROW:StockOptionPlanOneMember 2021-01-01 2021-03-31 0001360214 HROW:StockOptionPlanOneMember 2021-03-31 0001360214 HROW:StockOptionPlanMember 2021-03-31 0001360214 HROW:EmployeesAndConsultantMember HROW:StockOptionPlanMember 2020-01-01 2020-12-31 0001360214 HROW:EmployeesAndConsultantMember HROW:StockOptionPlanMember 2021-01-01 2021-03-31 0001360214 HROW:OptionsEmployeesMember 2021-01-01 2021-03-31 0001360214 HROW:RangeOneMember 2021-01-01 2021-03-31 0001360214 HROW:RangeOneMember 2021-03-31 0001360214 HROW:RangeTwoMember 2021-01-01 2021-03-31 0001360214 HROW:RangeTwoMember 2021-03-31 0001360214 HROW:RangeThreeMember 2021-01-01 2021-03-31 0001360214 HROW:RangeThreeMember 2021-03-31 0001360214 HROW:RangeFourMember 2021-01-01 2021-03-31 0001360214 HROW:RangeFourMember 2021-03-31 0001360214 HROW:StockOptionPlanMember 2021-01-01 2021-03-31 0001360214 HROW:StockOptionPlanMember 2020-01-01 2020-03-31 0001360214 HROW:EmployeesMember us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-03-31 0001360214 us-gaap:RestrictedStockUnitsRSUMember 2020-12-31 0001360214 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-03-31 0001360214 us-gaap:RestrictedStockUnitsRSUMember 2021-03-31 0001360214 HROW:UnvestedRSUMember 2021-03-31 0001360214 HROW:UnvestedRSUMember 2021-01-01 2021-03-31 0001360214 HROW:UnvestedRSUMember 2020-01-01 2020-03-31 0001360214 us-gaap:WarrantMember 2020-12-31 0001360214 us-gaap:WarrantMember 2021-01-01 2021-03-31 0001360214 us-gaap:WarrantMember 2021-03-31 0001360214 HROW:LenderWarrantsMember 2021-01-01 2021-03-31 0001360214 HROW:LenderWarrantsMember 2021-03-31 0001360214 HROW:SettlementWarrantsMember 2021-01-01 2021-03-31 0001360214 HROW:SettlementWarrantsMember 2021-03-31 0001360214 HROW:LenderWarrantsOneMember 2021-01-01 2021-03-31 0001360214 HROW:LenderWarrantsOneMember 2021-03-31 0001360214 HROW:EmployeesMember HROW:SellingGeneralAndAdministrativeMember 2021-01-01 2021-03-31 0001360214 HROW:EmployeesMember HROW:SellingGeneralAndAdministrativeMember 2020-01-01 2020-03-31 0001360214 srt:DirectorMember HROW:SellingGeneralAndAdministrativeMember 2021-01-01 2021-03-31 0001360214 srt:DirectorMember HROW:SellingGeneralAndAdministrativeMember 2020-01-01 2020-03-31 0001360214 HROW:RichardLLindstromMDMember HROW:KlarityLicenseAgreementMember 2017-04-01 2017-04-30 0001360214 HROW:InitialPaymentMember HROW:RichardLLindstromMDMember HROW:LicenseAgreementMember 2017-04-01 2017-04-30 0001360214 HROW:SecondPaymentMember HROW:RichardLLindstromMDMember HROW:LicenseAgreementMember 2017-04-01 2017-04-30 0001360214 HROW:FinalPaymentMember HROW:RichardLLindstromMDMember HROW:LicenseAgreementMember 2017-04-01 2017-04-30 0001360214 HROW:RichardLLindstromMDMember 2021-01-01 2021-03-31 0001360214 HROW:RichardLLindstromMDMember 2020-01-01 2020-03-31 0001360214 HROW:RichardLLindstromMDMember HROW:KlarityLicenseAgreementMember 2021-01-01 2021-03-31 0001360214 HROW:RichardLLindstromMDMember HROW:KlarityLicenseAgreementMember 2020-01-01 2020-03-31 0001360214 HROW:RichardLLindstromMDMember HROW:InjectableAssetPurchaseAgreementMember 2019-12-01 2019-12-31 0001360214 HROW:InitialPaymentMember HROW:RichardLLindstromMDMember HROW:InjectableAssetPurchaseAgreementMember 2019-12-01 2019-12-31 0001360214 HROW:RichardLLindstromMDMember HROW:InjectableAssetPurchaseAgreementMember 2021-01-01 2021-03-31 0001360214 HROW:RichardLLindstromMDMember HROW:InjectableAssetPurchaseAgreementMember 2020-01-01 2020-03-31 0001360214 HROW:DexycuAgreementMember 2021-01-01 2021-03-31 0001360214 srt:MinimumMember HROW:SalesAndMarketingAgreementsMember 2017-01-01 2019-12-31 0001360214 srt:MaximumMember HROW:SalesAndMarketingAgreementsMember 2017-01-01 2019-12-31 0001360214 HROW:SalesAndMarketingAgreementsMember 2021-01-01 2021-03-31 0001360214 HROW:SalesAndMarketingAgreementsMember 2020-01-01 2020-03-31 0001360214 us-gaap:OperatingSegmentsMember HROW:ImprimisRxMember 2021-01-01 2021-03-31 0001360214 us-gaap:OperatingSegmentsMember HROW:PharmaceuticalDrugDevelopmentMember 2021-01-01 2021-03-31 0001360214 us-gaap:OperatingSegmentsMember 2021-01-01 2021-03-31 0001360214 us-gaap:CorporateNonSegmentMember 2021-01-01 2021-03-31 0001360214 us-gaap:OperatingSegmentsMember us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-03-31 0001360214 us-gaap:OperatingSegmentsMember HROW:ImprimisRxMember 2020-01-01 2020-03-31 0001360214 us-gaap:OperatingSegmentsMember HROW:PharmaceuticalDrugDevelopmentMember 2020-01-01 2020-03-31 0001360214 us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0001360214 us-gaap:CorporateNonSegmentMember 2020-01-01 2020-03-31 0001360214 us-gaap:OperatingSegmentsMember us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-03-31 0001360214 HROW:ThreeMainSuppliersMember 2021-01-01 2021-03-31 0001360214 HROW:ThreeMainSuppliersMember 2020-01-01 2020-03-31 0001360214 HROW:MarkLBaumMember us-gaap:RestrictedStockUnitsRSUMember us-gaap:SubsequentEventMember 2021-04-01 2021-04-30 0001360214 HROW:MarkLBaumMember us-gaap:SubsequentEventMember 2021-04-01 2021-04-30 0001360214 HROW:AndrewRBollMember us-gaap:RestrictedStockUnitsRSUMember us-gaap:SubsequentEventMember 2021-04-01 2021-04-30 0001360214 HROW:AndrewRBollMember us-gaap:SubsequentEventMember 2021-04-01 2021-04-30 0001360214 us-gaap:SubsequentEventMember 2021-04-01 2021-04-30 0001360214 HROW:EtonStockSaleMember us-gaap:SubsequentEventMember HROW:UnderwrittenPublicOfferingMember 2021-04-01 2021-04-30 0001360214 HROW:EtonStockSaleMember us-gaap:SubsequentEventMember HROW:UnderwrittenPublicOfferingMember 2021-04-30 0001360214 HROW:EightPointSixTwentyFiveSeniorNotesDueTwentyTwentySixMember us-gaap:SubsequentEventMember 2021-04-30 0001360214 HROW:UnderwritersMember HROW:EightPointSixTwentyFiveSeniorNotesDueTwentyTwentySixMember us-gaap:SubsequentEventMember 2021-04-01 2021-04-30 0001360214 HROW:UnderwritersMember HROW:EightPointSixTwentyFiveSeniorNotesDueTwentyTwentySixMember us-gaap:SubsequentEventMember 2021-04-30 0001360214 HROW:EightPointSixTwentyFiveSeniorNotesDueTwentyTwentySixMember us-gaap:SubsequentEventMember 2021-04-01 2021-04-30 0001360214 HROW:SWKLoanMember us-gaap:SubsequentEventMember 2021-04-01 2021-04-30 0001360214 HROW:SeriesBCumulativePreferredStockMember us-gaap:SubsequentEventMember 2021-05-01 2021-05-11 0001360214 HROW:SeriesBCumulativePreferredStockMember us-gaap:SubsequentEventMember 2021-05-11 0001360214 us-gaap:SubsequentEventMember HROW:EllePharmaceuticalLLCMember 2021-05-11 0001360214 HROW:TGVHealthLLCMember us-gaap:SubsequentEventMember 2021-05-01 2021-05-11 0001360214 HROW:EllePharmaceuticalLLCMember us-gaap:SubsequentEventMember 2021-05-01 2021-05-11 0001360214 HROW:StowePharmaceuticalsIncMember us-gaap:SubsequentEventMember 2021-05-01 2021-05-11 iso4217:USD shares iso4217:USD shares pure utr:sqft 0001360214 false Q1 2021 --12-31 Non-accelerated Filer

10-Q true 2021-03-31 false 001-35814 Harrow Health, Inc. DE 45-0567010 102 Woodmont Blvd. Suite 610 Nashville TN 37205 (615) 733-4730 Common Stock, $0.001 par value per share HROW NASDAQ 8.625% Senior Notes due 2026 HROWL NASDAQ Yes Yes true false false 26582215

200000

6504000

4301000

25620000

28455000

3253000

2662000

4496000

3962000

763000

751000

40636000

40131000

4200000

4453000

6651000

6799000

1912000

1939000

465000

1314000

2056000

2506000

332000

56252000

57474000

5176000

3932000

1631000

2315000

3000

66000

1259000

2659000

2639000

597000

580000

8000

10074000

10799000

6496000

6652000

16000

17000

800000

708000

10996000

11670000

28382000

30646000

0.001

50000000

25983676

25749875

26000

105382000

104557000

-77183000

-77400000

28225000

27183000

-355000

27870000

26828000

56252000

57474000

14948000

11810000

495000

7000

15443000

11817000

3770000

3626000

11673000

8191000

8164000

8416000

592000

403000

8756000

8819000

2917000

-628000

-513000

-560000

-470000

-546000

-849000

-339000

-2835000

-10850000

1967000

-2700000

-12295000

217000

-12923000

217000

-12923000

-16000

217000

-12907000

0.01

-0.50

0.01

-0.50

26019255

25867568

27480622

25867568

25526931

26000

101728000

-74043000

27711000

-293000

27418000

91987

533000

-12907000

-16000

-12923000

25618918

26000

102261000

-86950000

15337000

-309000

15028000

25749875

26000

104557000

-77400000

27183000

-355000

26828000

11301

27000

230000

7500

-57000

855000

217000

25983676

26000

105382000

-77183000

28225000

-355000

27870000

217000

-12923000

464000

448000

40000 45000 148000 169000

19000

96000

160000

1967000 -2835000 -10850000 -849000 -339000 -470000 -546000

855000

533000

610000

20000

534000

688000

32000

8000

1105000

-337000

-684000

333000

-63000

3000

3208000

-550000

13000

53000

211000

220000

-224000

-273000

1000

2000

750000

-30000

-781000

-2000

2203000

-825000

4301000

4949000

6504000

4124000

6304000 3924000 200000 200000 6504000 4124000

415000

408000

41000 5000

NOTE 1. DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION Company and Background Harrow Health, Inc. (together with its subsidiaries, partially owned companies and royalty arrangements unless the context indicates or otherwise requires, the “Company” or “Harrow”) specializes in the development, production and sale of innovative medications that offer unique competitive advantages and serve unmet needs in the marketplace through its subsidiaries and deconsolidated companies. The Company owns one of the nation’s leading ophthalmology-focused pharmaceutical businesses, ImprimisRx. In addition to wholly owning ImprimisRx, the Company also has equity positions in Eton Pharmaceuticals, Inc. (“Eton”), Surface Ophthalmics, Inc. (“Surface”), and Melt Pharmaceuticals, Inc. (“Melt”), all companies that began as subsidiaries of Harrow. In 2020, Harrow created Visionology, Inc. (“Visionology”), which will launch an online eye health platform business. Harrow also owns royalty rights in various drug candidates being developed by Surface and Melt. Basis of Presentation The Company has prepared the accompanying unaudited condensed consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and in accordance with the rules and regulations of the U.S. Securities and Exchange Commission. Accordingly, they do not include all of the information and footnotes required by GAAP for audited financial statements. In the opinion of management, all adjustments (consisting of only normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2021 are not necessarily indicative of the results that may be expected for the year ending December 31, 2021 or for any other period. For further information, refer to the Company’s audited consolidated financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020. The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned and majority-owned subsidiaries. All inter-company accounts and transactions have been eliminated in consolidation. Harrow consolidates entities in which it has a controlling financial interest. The Company consolidates subsidiaries in which it holds and/or controls, directly or indirectly, more than 50% of the voting rights. All intercompany accounts and transactions have been eliminated in consolidation. The condensed consolidated balance sheets at March 31, 2021 and December 31, 2020 and the condensed consolidated statements of operations, stockholders’ equity and cash flows for the periods ended March 31, 2021 and 2020 include our accounts and those of our wholly owned subsidiaries, as well as our inactive majority owned subsidiaries Mayfield Pharmaceuticals, Inc. and Stowe Pharmaceuticals, Inc.

The Company consolidates subsidiaries in which it holds and/or controls, directly or indirectly, more than 50% of the voting rights.

NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The following represents an update for the three months ended March 31, 2021 to the significant accounting policies described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020. Risks, Uncertainties and Liquidity The Company is subject to certain regulatory standards, guidelines and inspections which could impact the Company’s ability to make, dispense, and sell certain products. If the Company was required to cease compounding and selling certain products as a result of regulatory guidelines or inspections, this may have a material impact on the Company’s financial condition, liquidity and results of operations. Segments The Company’s chief operating decision-maker is its Chief Executive Officer who makes resource allocation decisions and assesses performance based on financial information of our operating segments. The Company has identified two operating segments as reportable segments. See Note 16 for more information regarding the Company’s reportable segments. Noncontrolling Interests The Company recognizes any noncontrolling interest as a separate line item in equity in the condensed consolidated financial statements. A noncontrolling interest represents the portion of equity ownership in a less-than-wholly-owned subsidiary not attributable to the Company. Generally, any interest that holds less than 50% of the outstanding voting shares is deemed to be a noncontrolling interest; however, there are other factors, such as decision-making rights, that are considered as well. The Company includes the amount of net income (loss) attributable to noncontrolling interests in consolidated net income (loss) on the face of the condensed consolidated statements of operations. The Company provides in the condensed consolidated statements of stockholders’ equity a reconciliation at the beginning and the end of the period of the carrying amount of total equity, equity attributable to the parent, and equity attributable to the noncontrolling interest that separately discloses: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"> <tr style="vertical-align: top"> <td style="width: 0.25in"> </td> <td style="width: 0.25in">(1)</td> <td style="text-align: justify">Net income or loss;</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"> <tr style="vertical-align: top"> <td style="width: 0.25in"> </td> <td style="width: 0.25in">(2)</td> <td style="text-align: justify">transactions with owners acting in their capacity as owners, showing separately contributions from and distributions to owners; and</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"> <tr style="vertical-align: top"> <td style="width: 0.25in"> </td> <td style="width: 0.25in">(3)</td> <td style="text-align: justify">each component of other income or loss.</td></tr> </table> Basic and Diluted Net Income (Loss) per Common Share Basic net income (loss) per common share is computed by dividing net income (loss) attributable to common stockholders for the period by the weighted average number of common shares outstanding during the period. Diluted net income (loss) per share is computed by dividing the net income (loss) attributable to common stockholders for the period by the weighted average number of common and common equivalent shares, such as stock options, unvested restricted stock units (“RSUs”) and warrants, outstanding during the period. Basic and diluted net income (loss) per share is computed using the weighted average number of shares of common stock outstanding during the period. Common equivalent shares (using the treasury stock or “if converted” method) from stock options, RSUs and warrants were 5,486,678 and 5,253,638 at March 31, 2021 and 2020, respectively. For the three months ended March 31, 2020, the common equivalent shares are excluded in the calculation of diluted net loss per share because the effect is anti-dilutive. Included in the basic and diluted net income (loss) per share calculation were RSUs awarded to directors that had vested, but the issuance and delivery of the shares are deferred until the director resigns. The number of shares underlying vested RSUs at March 31, 2021 and 2020 was 223,219 and 244,460, respectively. The following table shows the computation of basic net income (loss) per share of common stock for the three months ended March 31, 2021 and 2020: SCHEDULE OF BASIC EARNINGS PER COMMON SHARE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" id="xdx_493_20210101__20210331_zPi7zyPeEac8" style="border-bottom: Black 1.5pt solid; display: none; text-align: center">2021</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="font-weight: bold; padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" id="xdx_498_20200101__20200331_z4vO7yhym6va" style="border-bottom: Black 1.5pt solid; display: none; font-weight: bold; text-align: center">2020</td> <td style="font-weight: bold; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1.5pt"> </td> <td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Three Months Ended March 31,</td> <td style="font-weight: bold; padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="font-weight: bold; padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td> <td style="font-weight: bold; padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40E_ecustom--NetIncomeLoss1_pn3n3_zc645dCJ6lC3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Numerator – net income (loss) attributable to Harrow Health, Inc.</td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 16%; text-align: right">217</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 16%; text-align: right">(12,907</td> <td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pii_zC4KsWBzMWoh" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">Denominator – weighted average number of shares outstanding, basic</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right">26,019,255</td> <td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right">25,867,568</td> <td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--EarningsPerShareBasic_pii_zQUl3az4Rwkl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">Net income (loss) per share, basic</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">0.01</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">(0.50</td> <td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> For the three months ended March 31, 2021, the Company computed diluted net income per share using the weighted-average number of common shares and dilutive common equivalent shares outstanding during the period. Diluted common equivalent shares for the three months ended March 31, 2021, consisted of the following: SCHEDULE OF DILUTED COMMON EQUIVALENT SHARES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"> March 31, 2021</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Diluted shares related to:</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 79%">Warrants</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pii_c20210101__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zUwKBZeqAT32" style="width: 18%; text-align: right" title="Dilutive common equivalent shares">576,275</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Stock options</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td> <td id="xdx_98E_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pii_c20210101__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_z0MRBuMHCxL6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Dilutive common equivalent shares">885,092</td> <td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Dilutive common equivalent shares</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td id="xdx_98C_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pii_c20210101__20210331_z0qu6wJJqPT1" style="border-bottom: Black 2.5pt double; text-align: right" title="Dilutive common equivalent shares">1,461,367</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The following table shows the computation of diluted net income (loss) per share using the weighted-average number of common shares and dilutive common equivalent shares outstanding for the three months ended March 31, 2021 and 2020: SCHEDULE OF DILUTED EARNINGS PER COMMON SHARE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" id="xdx_498_20210101__20210331_zBL2Lqi6dxL6" style="border-bottom: Black 1.5pt solid; display: none; font-weight: bold; text-align: center">2021</td> <td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" id="xdx_491_20200101__20200331_z8jUed241Iyj" style="border-bottom: Black 1.5pt solid; display: none; font-weight: bold; text-align: center">2020</td> <td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">For the Three Months Ended March 31,</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td> <td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td> <td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40C_eus-gaap--NetIncomeLoss_pn3n3_zTbFFUIPs6j1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 62%; text-align: left; padding-bottom: 2.5pt">Numerator – net income (loss)</td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">217</td> <td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">(12,907</td> <td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pii_zXYFOLngVfk6" style="vertical-align: bottom; background-color: White"> <td>Weighted average number of shares outstanding, basic</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">26,019,255</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">25,867,568</td> <td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--IncrementalCommonSharesAttributableDilutiveCommonEquivalents_pii_zJoZvSt37bfb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Dilutive common equivalent shares</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right">1,461,367</td> <td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--IncrementalCommonSharesAttributableToContingentlyIssuableShares_pii_z0815TRoogn8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Denominator – number of shares used for diluted earnings per share computation</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right">27,480,622</td> <td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right">25,867,568</td> <td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--EarningsPerShareDiluted_pii_uUSDPShares_zyjXajzAGMX1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net income (loss) per share, diluted</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">0.01</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">(0.50</td> <td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> Investment in Eton Pharmaceuticals, Inc. As of March 31, 2021, the Company owned 3,500,000 shares of Eton common stock, which represented approximately <span id="xdx_907_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pii_dp_c20210331__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_zyJCyQFRmkW5" title="Equity method investment, ownership percentage">14.3% of the equity interests of Eton. At March 31, 2021, the fair market value of Eton’s common stock was $7.32 per share. In accordance with the Accounting Standards Update (“ASU”) 2016-01, Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities, the Company recorded an unrealized investment loss from its Eton common stock position of $2,835 and $10,850 during the three months ended March 31, 2021 and 2020, respectively, related to the change in fair market value of its investment in Eton during the measurement period. As of March 31, 2021, the fair market value of the Company’s investment in Eton was $25,620. During the three months ended March 31, 2021, Mark L. Baum, the Company’s Chief Executive Officer, resigned as a member of the board of directors of Eton. In April 2021, the Company sold <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pii_c20210401__20210430__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zNNsX5syh168" title="Stock issued during period">1,518,000 shares of its Eton common stock (see Note 17 for more information related to this subsequent event). In light of these events, the Company has determined that Eton is no longer a related party. Investment in Melt Pharmaceuticals, Inc. – Related Party The Company owns 3,500,000 common shares (which is approximately <span id="xdx_904_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pii_dp_c20210331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zOLGCD7cg7D8" title="Equity method investment, ownership percentage">44% of the equity interests as of March 31, 2021) of Melt and uses the equity method of accounting for this investment, as management has determined that the Company has the ability to exercise significant influence over the operating and financial decisions of Melt. Under this method, the Company recognizes earnings and losses in Melt in its condensed consolidated financial statements and adjusts the carrying amount of its investment in Melt accordingly. The Company’s share of earnings and losses are based on the Company’s ownership interest of Melt. Any intra-entity profits and losses are eliminated. During the three months ended March 31, 2021 and 2020, the Company recorded equity in the net losses of Melt of $470 and $546, respectively. As of March 31, 2021 and December 31, 2020, the Company’s investment in Melt was $2,056 and $2,506, respectively, which includes $881 and $851, respectively, due from Melt for reimbursable expenses and amounts due under a Management Services Agreement between the Company and Melt (the “Melt MSA”). See Note 4 for more information and related party disclosure regarding Melt. Investment in Surface Ophthalmics, Inc. – Related Party The Company owns 3,500,000 common shares (which is approximately <span id="xdx_90A_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pii_dp_c20210331__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_zgBV0P2Zedbh" title="Equity method investment, ownership percentage">30% of the equity interests as of March 31, 2021) of Surface and uses the equity method of accounting for this investment, as management has determined that the Company has the ability to exercise significant influence over the operating and financial decisions of Surface. Under this method, the Company recognizes earnings and losses in Surface in its condensed consolidated financial statements and adjusts the carrying amount of its investment in Surface accordingly. The Company’s share of earnings and losses are based on the Company’s ownership interest of Surface. Any intra-entity profits and losses are eliminated. The Company recorded equity in the net losses of Surface of $849 and $339 during the three months ended March 31, 2021 and 2020, respectively. As of March 31, 2021 and December 31, 2020, the Company’s investment in Surface was $465 and $1,314, respectively. See Note 5 for more information and related party disclosure regarding Surface. Recently Adopted Accounting Pronouncements In December 2019, the FASB issued ASU 2019-12, Income Taxes: Simplifying the Accounting for Income Taxes, which simplifies the accounting for income taxes. This guidance became effective for the Company on January 1, 2021 on a prospective basis. Adoption of this ASU did not have a material impact on the Company’s condensed consolidated financial statements.

Risks, Uncertainties and Liquidity The Company is subject to certain regulatory standards, guidelines and inspections which could impact the Company’s ability to make, dispense, and sell certain products. If the Company was required to cease compounding and selling certain products as a result of regulatory guidelines or inspections, this may have a material impact on the Company’s financial condition, liquidity and results of operations.

Segments The Company’s chief operating decision-maker is its Chief Executive Officer who makes resource allocation decisions and assesses performance based on financial information of our operating segments. The Company has identified two operating segments as reportable segments. See Note 16 for more information regarding the Company’s reportable segments.

Noncontrolling Interests The Company recognizes any noncontrolling interest as a separate line item in equity in the condensed consolidated financial statements. A noncontrolling interest represents the portion of equity ownership in a less-than-wholly-owned subsidiary not attributable to the Company. Generally, any interest that holds less than 50% of the outstanding voting shares is deemed to be a noncontrolling interest; however, there are other factors, such as decision-making rights, that are considered as well. The Company includes the amount of net income (loss) attributable to noncontrolling interests in consolidated net income (loss) on the face of the condensed consolidated statements of operations. The Company provides in the condensed consolidated statements of stockholders’ equity a reconciliation at the beginning and the end of the period of the carrying amount of total equity, equity attributable to the parent, and equity attributable to the noncontrolling interest that separately discloses: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"> <tr style="vertical-align: top"> <td style="width: 0.25in"> </td> <td style="width: 0.25in">(1)</td> <td style="text-align: justify">Net income or loss;</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"> <tr style="vertical-align: top"> <td style="width: 0.25in"> </td> <td style="width: 0.25in">(2)</td> <td style="text-align: justify">transactions with owners acting in their capacity as owners, showing separately contributions from and distributions to owners; and</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"> <tr style="vertical-align: top"> <td style="width: 0.25in"> </td> <td style="width: 0.25in">(3)</td> <td style="text-align: justify">each component of other income or loss.</td></tr> </table>

Generally, any interest that holds less than 50% of the outstanding voting shares is deemed to be a noncontrolling interest; however, there are other factors, such as decision-making rights, that are considered as well.

Basic and Diluted Net Income (Loss) per Common Share Basic net income (loss) per common share is computed by dividing net income (loss) attributable to common stockholders for the period by the weighted average number of common shares outstanding during the period. Diluted net income (loss) per share is computed by dividing the net income (loss) attributable to common stockholders for the period by the weighted average number of common and common equivalent shares, such as stock options, unvested restricted stock units (“RSUs”) and warrants, outstanding during the period. Basic and diluted net income (loss) per share is computed using the weighted average number of shares of common stock outstanding during the period. Common equivalent shares (using the treasury stock or “if converted” method) from stock options, RSUs and warrants were 5,486,678 and 5,253,638 at March 31, 2021 and 2020, respectively. For the three months ended March 31, 2020, the common equivalent shares are excluded in the calculation of diluted net loss per share because the effect is anti-dilutive. Included in the basic and diluted net income (loss) per share calculation were RSUs awarded to directors that had vested, but the issuance and delivery of the shares are deferred until the director resigns. The number of shares underlying vested RSUs at March 31, 2021 and 2020 was 223,219 and 244,460, respectively. The following table shows the computation of basic net income (loss) per share of common stock for the three months ended March 31, 2021 and 2020: SCHEDULE OF BASIC EARNINGS PER COMMON SHARE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" id="xdx_493_20210101__20210331_zPi7zyPeEac8" style="border-bottom: Black 1.5pt solid; display: none; text-align: center">2021</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="font-weight: bold; padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" id="xdx_498_20200101__20200331_z4vO7yhym6va" style="border-bottom: Black 1.5pt solid; display: none; font-weight: bold; text-align: center">2020</td> <td style="font-weight: bold; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1.5pt"> </td> <td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Three Months Ended March 31,</td> <td style="font-weight: bold; padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="font-weight: bold; padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td> <td style="font-weight: bold; padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40E_ecustom--NetIncomeLoss1_pn3n3_zc645dCJ6lC3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Numerator – net income (loss) attributable to Harrow Health, Inc.</td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 16%; text-align: right">217</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 16%; text-align: right">(12,907</td> <td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pii_zC4KsWBzMWoh" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">Denominator – weighted average number of shares outstanding, basic</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right">26,019,255</td> <td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right">25,867,568</td> <td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--EarningsPerShareBasic_pii_zQUl3az4Rwkl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">Net income (loss) per share, basic</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">0.01</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">(0.50</td> <td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> For the three months ended March 31, 2021, the Company computed diluted net income per share using the weighted-average number of common shares and dilutive common equivalent shares outstanding during the period. Diluted common equivalent shares for the three months ended March 31, 2021, consisted of the following: SCHEDULE OF DILUTED COMMON EQUIVALENT SHARES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"> March 31, 2021</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Diluted shares related to:</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 79%">Warrants</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pii_c20210101__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zUwKBZeqAT32" style="width: 18%; text-align: right" title="Dilutive common equivalent shares">576,275</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Stock options</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td> <td id="xdx_98E_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pii_c20210101__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_z0MRBuMHCxL6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Dilutive common equivalent shares">885,092</td> <td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Dilutive common equivalent shares</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td id="xdx_98C_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pii_c20210101__20210331_z0qu6wJJqPT1" style="border-bottom: Black 2.5pt double; text-align: right" title="Dilutive common equivalent shares">1,461,367</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The following table shows the computation of diluted net income (loss) per share using the weighted-average number of common shares and dilutive common equivalent shares outstanding for the three months ended March 31, 2021 and 2020: SCHEDULE OF DILUTED EARNINGS PER COMMON SHARE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" id="xdx_498_20210101__20210331_zBL2Lqi6dxL6" style="border-bottom: Black 1.5pt solid; display: none; font-weight: bold; text-align: center">2021</td> <td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" id="xdx_491_20200101__20200331_z8jUed241Iyj" style="border-bottom: Black 1.5pt solid; display: none; font-weight: bold; text-align: center">2020</td> <td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">For the Three Months Ended March 31,</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td> <td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td> <td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40C_eus-gaap--NetIncomeLoss_pn3n3_zTbFFUIPs6j1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 62%; text-align: left; padding-bottom: 2.5pt">Numerator – net income (loss)</td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">217</td> <td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">(12,907</td> <td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pii_zXYFOLngVfk6" style="vertical-align: bottom; background-color: White"> <td>Weighted average number of shares outstanding, basic</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">26,019,255</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">25,867,568</td> <td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--IncrementalCommonSharesAttributableDilutiveCommonEquivalents_pii_zJoZvSt37bfb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Dilutive common equivalent shares</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right">1,461,367</td> <td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--IncrementalCommonSharesAttributableToContingentlyIssuableShares_pii_z0815TRoogn8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Denominator – number of shares used for diluted earnings per share computation</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right">27,480,622</td> <td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right">25,867,568</td> <td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--EarningsPerShareDiluted_pii_uUSDPShares_zyjXajzAGMX1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net income (loss) per share, diluted</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">0.01</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">(0.50</td> <td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table>

5486678 5253638 223219 244460

The following table shows the computation of basic net income (loss) per share of common stock for the three months ended March 31, 2021 and 2020: SCHEDULE OF BASIC EARNINGS PER COMMON SHARE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" id="xdx_493_20210101__20210331_zPi7zyPeEac8" style="border-bottom: Black 1.5pt solid; display: none; text-align: center">2021</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="font-weight: bold; padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" id="xdx_498_20200101__20200331_z4vO7yhym6va" style="border-bottom: Black 1.5pt solid; display: none; font-weight: bold; text-align: center">2020</td> <td style="font-weight: bold; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1.5pt"> </td> <td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Three Months Ended March 31,</td> <td style="font-weight: bold; padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="font-weight: bold; padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td> <td style="font-weight: bold; padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40E_ecustom--NetIncomeLoss1_pn3n3_zc645dCJ6lC3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Numerator – net income (loss) attributable to Harrow Health, Inc.</td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 16%; text-align: right">217</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 16%; text-align: right">(12,907</td> <td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pii_zC4KsWBzMWoh" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">Denominator – weighted average number of shares outstanding, basic</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right">26,019,255</td> <td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right">25,867,568</td> <td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--EarningsPerShareBasic_pii_zQUl3az4Rwkl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">Net income (loss) per share, basic</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">0.01</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">(0.50</td> <td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table>

217000 -12907000

26019255

25867568

0.01

-0.50

For the three months ended March 31, 2021, the Company computed diluted net income per share using the weighted-average number of common shares and dilutive common equivalent shares outstanding during the period. Diluted common equivalent shares for the three months ended March 31, 2021, consisted of the following: SCHEDULE OF DILUTED COMMON EQUIVALENT SHARES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"> March 31, 2021</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Diluted shares related to:</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 79%">Warrants</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pii_c20210101__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zUwKBZeqAT32" style="width: 18%; text-align: right" title="Dilutive common equivalent shares">576,275</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Stock options</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td> <td id="xdx_98E_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pii_c20210101__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_z0MRBuMHCxL6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Dilutive common equivalent shares">885,092</td> <td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Dilutive common equivalent shares</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td id="xdx_98C_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pii_c20210101__20210331_z0qu6wJJqPT1" style="border-bottom: Black 2.5pt double; text-align: right" title="Dilutive common equivalent shares">1,461,367</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

576275

885092

1461367

The following table shows the computation of diluted net income (loss) per share using the weighted-average number of common shares and dilutive common equivalent shares outstanding for the three months ended March 31, 2021 and 2020: SCHEDULE OF DILUTED EARNINGS PER COMMON SHARE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" id="xdx_498_20210101__20210331_zBL2Lqi6dxL6" style="border-bottom: Black 1.5pt solid; display: none; font-weight: bold; text-align: center">2021</td> <td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" id="xdx_491_20200101__20200331_z8jUed241Iyj" style="border-bottom: Black 1.5pt solid; display: none; font-weight: bold; text-align: center">2020</td> <td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">For the Three Months Ended March 31,</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td> <td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td> <td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40C_eus-gaap--NetIncomeLoss_pn3n3_zTbFFUIPs6j1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 62%; text-align: left; padding-bottom: 2.5pt">Numerator – net income (loss)</td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">217</td> <td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td> <td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">(12,907</td> <td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pii_zXYFOLngVfk6" style="vertical-align: bottom; background-color: White"> <td>Weighted average number of shares outstanding, basic</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">26,019,255</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">25,867,568</td> <td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--IncrementalCommonSharesAttributableDilutiveCommonEquivalents_pii_zJoZvSt37bfb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Dilutive common equivalent shares</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right">1,461,367</td> <td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--IncrementalCommonSharesAttributableToContingentlyIssuableShares_pii_z0815TRoogn8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Denominator – number of shares used for diluted earnings per share computation</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right">27,480,622</td> <td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right">25,867,568</td> <td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--EarningsPerShareDiluted_pii_uUSDPShares_zyjXajzAGMX1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net income (loss) per share, diluted</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">0.01</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">(0.50</td> <td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table>

217000

-12907000

26019255

25867568

1461367

27480622

25867568

0.01

-0.50

Investment in Eton Pharmaceuticals, Inc. As of March 31, 2021, the Company owned 3,500,000 shares of Eton common stock, which represented approximately <span id="xdx_907_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pii_dp_c20210331__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_zyJCyQFRmkW5" title="Equity method investment, ownership percentage">14.3% of the equity interests of Eton. At March 31, 2021, the fair market value of Eton’s common stock was $7.32 per share. In accordance with the Accounting Standards Update (“ASU”) 2016-01, Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities, the Company recorded an unrealized investment loss from its Eton common stock position of $2,835 and $10,850 during the three months ended March 31, 2021 and 2020, respectively, related to the change in fair market value of its investment in Eton during the measurement period. As of March 31, 2021, the fair market value of the Company’s investment in Eton was $25,620. During the three months ended March 31, 2021, Mark L. Baum, the Company’s Chief Executive Officer, resigned as a member of the board of directors of Eton. In April 2021, the Company sold <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pii_c20210401__20210430__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zNNsX5syh168" title="Stock issued during period">1,518,000 shares of its Eton common stock (see Note 17 for more information related to this subsequent event). In light of these events, the Company has determined that Eton is no longer a related party.

3500000

0.143

7.32

2835000

10850000

25620000

1518000

Investment in Melt Pharmaceuticals, Inc. – Related Party The Company owns 3,500,000 common shares (which is approximately <span id="xdx_904_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pii_dp_c20210331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zOLGCD7cg7D8" title="Equity method investment, ownership percentage">44% of the equity interests as of March 31, 2021) of Melt and uses the equity method of accounting for this investment, as management has determined that the Company has the ability to exercise significant influence over the operating and financial decisions of Melt. Under this method, the Company recognizes earnings and losses in Melt in its condensed consolidated financial statements and adjusts the carrying amount of its investment in Melt accordingly. The Company’s share of earnings and losses are based on the Company’s ownership interest of Melt. Any intra-entity profits and losses are eliminated. During the three months ended March 31, 2021 and 2020, the Company recorded equity in the net losses of Melt of $470 and $546, respectively. As of March 31, 2021 and December 31, 2020, the Company’s investment in Melt was $2,056 and $2,506, respectively, which includes $881 and $851, respectively, due from Melt for reimbursable expenses and amounts due under a Management Services Agreement between the Company and Melt (the “Melt MSA”). See Note 4 for more information and related party disclosure regarding Melt. 3500000

0.44

470000

546000

2056000

2506000

881000

851000

Investment in Surface Ophthalmics, Inc. – Related Party The Company owns 3,500,000 common shares (which is approximately <span id="xdx_90A_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pii_dp_c20210331__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_zgBV0P2Zedbh" title="Equity method investment, ownership percentage">30% of the equity interests as of March 31, 2021) of Surface and uses the equity method of accounting for this investment, as management has determined that the Company has the ability to exercise significant influence over the operating and financial decisions of Surface. Under this method, the Company recognizes earnings and losses in Surface in its condensed consolidated financial statements and adjusts the carrying amount of its investment in Surface accordingly. The Company’s share of earnings and losses are based on the Company’s ownership interest of Surface. Any intra-entity profits and losses are eliminated. The Company recorded equity in the net losses of Surface of $849 and $339 during the three months ended March 31, 2021 and 2020, respectively. As of March 31, 2021 and December 31, 2020, the Company’s investment in Surface was $465 and $1,314, respectively. See Note 5 for more information and related party disclosure regarding Surface. 3500000

0.30

849000

339000

465000

1314000

Recently Adopted Accounting Pronouncements In December 2019, the FASB issued ASU 2019-12, Income Taxes: Simplifying the Accounting for Income Taxes, which simplifies the accounting for income taxes. This guidance became effective for the Company on January 1, 2021 on a prospective basis. Adoption of this ASU did not have a material impact on the Company’s condensed consolidated financial statements.

NOTE 3. REVENUES The Company accounts for contracts with customers in accordance with ASC 606, Revenues from Contracts with Customers. The Company has three primary streams of revenue: (1) revenue recognized from our sale of products within our pharmacy services, (2) revenue recognized from a commission agreement with a third party and (3) revenue recognized from intellectual property license and asset purchase agreements. Product Revenues from Pharmacy Services The Company sells prescription drugs directly through our pharmacy and outsourcing facility network. Revenue from our pharmacy services division includes: (i) the portion of the price the client pays directly to us, net of any volume-related or other discounts paid back to the client, (ii) the price paid to us by individuals, and (iii) customer copayments made directly to the pharmacy network. Sales taxes are not included in revenue. Following the core principle of ASC 606, we have identified the following: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.5in"> </td> <td style="width: 0.25in">1.</td> <td style="text-align: justify">Identify the contract(s) with a customer: A contract exists with a customer at the time the prescription or order is received by the Company. </td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td>2.</td> <td style="text-align: justify">Identify the performance obligations in the contract: The order received contains the performance obligations to be met, in almost all cases the product the customer is wishing to receive. If we are unable to meet the performance obligation, the customer is notified. </td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td>3.</td> <td style="text-align: justify">Determine the transaction price: the transaction price is based on the product being sold to the customer and any related customer discounts. These amounts are pre-determined and built into our order management software. </td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td>4.</td> <td style="text-align: justify">Allocate the transaction price to the performance obligations in the contract: The transaction price associated with the product(s) being ordered is allocated according to the pre-determined amounts.</td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td>5.</td> <td style="text-align: justify">Recognize revenue when (or as) the entity satisfies a performance obligation: At the time of shipment from the pharmacy or outsourcing facility, the performance obligation has been met. </td></tr> </table> The following revenue recognition policy has been established for the pharmacy services division: Revenues generated from prescription or office use drugs sold by our pharmacies and outsourcing facility are recognized when the prescription is shipped. At the time of shipment, the pharmacy services division has performed substantially all of its obligations under its client contracts and does not experience a significant level of returns or reshipments. Determination of criteria (3) and (4) is based on management’s judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. The Company records reductions to revenue for discounts at the time of the initial sale. Estimated returns and allowances and other adjustments are provided for in the same period during which the related sales are recorded and are based on actual returns history. The rate of returns is analyzed annually to determine historical returns experience. If the historical data we use to calculate these estimates do not properly reflect future returns, then a change in the allowance would be made in the period in which such a determination is made and revenues in that period could be materially affected. The Company will defer any revenues received for a product that has not been delivered or is subject to refund until such time that the Company and the customer jointly determine that the product has been delivered and no refund will be required. Commission Revenues During the year ended December 31, 2020, the Company entered into an agreement whereby it is paid a fee calculated based on sales it generates from a pharmaceutical product that is owned by a third party. The revenue earned from this arrangement is recognized at the time a customer has ordered the pharmaceutical product and it has shipped from the third party (or one of its distributors or affiliates), at which point there is no future performance obligation required by the Company and no consequential continuing involvement on the part of the Company to recognize the associated revenue. Intellectual Property License Revenues As of March 31, 2021, we are party to four intellectual property licenses and asset purchase agreements in which we have agreed to grant a license and which provide a customer with the right to access the Company’s intellectual property. License arrangements may consist of non-refundable upfront license fees, data transfer fees, research reimbursement payments, exclusive license rights to patented or patent pending compounds, technology access fees, and various performance or sales milestones. These arrangements can be multiple-element arrangements, the revenue of which is recognized at the point in time at which the performance obligation is met. Non-refundable fees that are not contingent on any future performance by the Company and require no consequential continuing involvement on the part of the Company are recognized as revenue when the license term commences and the licensed data, technology, compounded drug preparation and/or other deliverable is delivered. Such deliverables may include physical quantities of compounded drug preparations, design of the compounded drug preparations and structure-activity relationships, the conceptual framework and mechanism of action, and rights to the patents or patent applications for such compounded drug preparations. The Company defers recognition of non-refundable fees if it has continuing performance obligations without which the technology, right, product or service conveyed in conjunction with the non-refundable fee has no utility to the licensee and that are separate and independent of the Company’s performance under the other elements of the arrangement. In addition, if the Company’s continued involvement is required, through research and development services that are related to its proprietary know-how and expertise of the delivered technology or can only be performed by the Company, then such non-refundable fees are deferred and recognized over the period of continuing involvement. Guaranteed minimum annual royalties are recognized on a straight-line basis over the applicable term. Revenue disaggregated by revenue source for the three months ended March 31, 2021 and 2020, consists of the following: SCHEDULE OF DISAGGREGATED REVENUE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td> <td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Three Months Ended March 31,</td> <td style="font-weight: bold; padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="font-weight: bold; padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td> <td style="font-weight: bold; padding-bottom: 1.5pt; text-align: center"> </td> <td style="font-weight: bold; padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td> <td style="font-weight: bold; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 58%; text-align: left">Product sales, net</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20210331__srt--ProductOrServiceAxis__custom--ProductSalesNetMember_zVzLJ9dv7l97" style="width: 18%; text-align: right" title="Total Revenues">14,948</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20200331__srt--ProductOrServiceAxis__custom--ProductSalesNetMember_z3n7I0OoDoq3" style="width: 18%; text-align: right" title="Total Revenues">11,810</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Commissions</td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20210331__srt--ProductOrServiceAxis__custom--CommissionsMember_z4rPoQfMKpH6" style="text-align: right" title="Total Revenues">485</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20200331__srt--ProductOrServiceAxis__custom--CommissionsMember_zJe23GcfK4pd" style="text-align: right" title="Total Revenues">-</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Licenses</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td> <td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20210331__srt--ProductOrServiceAxis__us-gaap--LicenseMember_zQiFMNwInjf2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Revenues">10</td> <td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td> <td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20200331__srt--ProductOrServiceAxis__us-gaap--LicenseMember_zYDPaICxc2U6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Revenues">7</td> <td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 2.5pt; text-align: left">Total revenues</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20210331_zhNUT7fMpPDk" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Revenues">15,443</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20200331_zne2syX7fdVb" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Revenues">11,817</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Deferred revenue and customer deposits at March 31, 2021 and December 31, 2020, were $3 and $66, respectively. All deferred revenue and customer deposit amounts at December 31, 2020 were recognized as revenue during the three months ended March 31, 2021.

Revenue disaggregated by revenue source for the three months ended March 31, 2021 and 2020, consists of the following: SCHEDULE OF DISAGGREGATED REVENUE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td> <td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Three Months Ended March 31,</td> <td style="font-weight: bold; padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="font-weight: bold; padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td> <td style="font-weight: bold; padding-bottom: 1.5pt; text-align: center"> </td> <td style="font-weight: bold; padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td> <td style="font-weight: bold; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 58%; text-align: left">Product sales, net</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20210331__srt--ProductOrServiceAxis__custom--ProductSalesNetMember_zVzLJ9dv7l97" style="width: 18%; text-align: right" title="Total Revenues">14,948</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20200331__srt--ProductOrServiceAxis__custom--ProductSalesNetMember_z3n7I0OoDoq3" style="width: 18%; text-align: right" title="Total Revenues">11,810</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Commissions</td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20210331__srt--ProductOrServiceAxis__custom--CommissionsMember_z4rPoQfMKpH6" style="text-align: right" title="Total Revenues">485</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20200331__srt--ProductOrServiceAxis__custom--CommissionsMember_zJe23GcfK4pd" style="text-align: right" title="Total Revenues">-</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Licenses</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td> <td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20210331__srt--ProductOrServiceAxis__us-gaap--LicenseMember_zQiFMNwInjf2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Revenues">10</td> <td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td> <td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20200331__srt--ProductOrServiceAxis__us-gaap--LicenseMember_zYDPaICxc2U6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Revenues">7</td> <td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 2.5pt; text-align: left">Total revenues</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20210331_zhNUT7fMpPDk" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Revenues">15,443</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20200331_zne2syX7fdVb" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Revenues">11,817</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

14948000

11810000

485000

10000

7000

15443000

11817000

3000

66000

<p id="xdx_807_eus-gaap--InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_zabrlPnhKOF" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">NOTE 4. INVESTMENT IN MELT PHARMACEUTICALS, INC. - RELATED PARTY TRANSACTIONS In December 2018, the Company entered into an asset purchase agreement with Melt (the “Melt Asset Purchase Agreement”). Pursuant to the terms of the Melt Asset Purchase Agreement, Melt was assigned certain intellectual property and related rights from the Company to develop, formulate, make, sell, and sub-license certain Company conscious sedation and analgesia related formulations (collectively, the “Melt Products”). Under the terms of the Melt Asset Purchase Agreement, Melt is required to make mid-single-digit royalty payments to the Company on net sales of the Melt Products while any patent rights remain outstanding, as well as other conditions. In January and March 2019, the Company entered into the Melt Series A Preferred Stock Agreement. See also Note 2, under the subheading Investment in Melt Pharmaceuticals, Inc. In February 2019, the Company and Melt entered into the Melt MSA, whereby the Company provides to Melt certain administrative services and support, including bookkeeping, web services and human resources related activities, and Melt is required to pay the Company a monthly amount of $<span id="xdx_90F_eus-gaap--AdministrativeFeesExpense_pn3n3_c20190201__20190228__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember__us-gaap--TypeOfArrangementAxis__custom--ManagementServicesAgreementMember_zKFGXMiGXDce" title="Administrative fees expense">10. As of March 31, 2021 and December 31, 2020, the Company was due $<span id="xdx_90E_eus-gaap--DueFromRelatedParties_iI_pn3n3_c20210331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember__us-gaap--TypeOfArrangementAxis__custom--ManagementServicesAgreementMember_zOYm8rYUqYfg" title="Due from related parties">881 and $<span id="xdx_90C_eus-gaap--DueFromRelatedParties_iI_pn3n3_c20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember__us-gaap--TypeOfArrangementAxis__custom--ManagementServicesAgreementMember_znymZk2XCEy5" title="Due from related parties">851, respectively, from Melt for reimbursable expenses and amounts due under the Melt MSA. Melt did not make any payments to the Company during the three months ended March 31, 2021. The Company’s Chief Executive Officer, Mark L. Baum, and Chief Medical Officer, Larry Dillaha, M.D. are members of the Melt board of directors, and several employees of the Company (including Mr. Baum, Dr. Dillaha and the Company’s Chief Financial Officer, Andrew R. Boll) entered into consulting agreements and provide consulting services to Melt. The unaudited condensed results of operations information of Melt is summarized below: SCHEDULE OF CONDENSED INCOME STATEMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td> <td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center">For the Three Months Ended </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: center" title="Revenues, net">March 31, 2021</td> <td style="text-align: left"> </td> <td> </td> <td colspan="2" style="text-align: center">March 31, 2020</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Revenues, net</td> <td> </td> <td style="text-align: left">$</td> <td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20210331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zBATsNPPXkvl" style="text-align: right" title="Revenues, net">-</td> <td style="text-align: left"> </td> <td> </td> <td>$</td> <td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20200331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zQn46EizSQi1" style="text-align: right" title="Revenues, net">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left; padding-bottom: 1.5pt">Loss from operations</td> <td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--OperatingIncomeLoss_pn3n3_c20210101__20210331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zhR3QPNYaRCe" style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right" title="Loss from operations">(1,099</td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td> <td style="padding-bottom: 1.5pt; width: 2%"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%"> </td> <td id="xdx_984_eus-gaap--OperatingIncomeLoss_pn3n3_c20200101__20200331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zmIkVdjcPdDb" style="border-bottom: Black 1.5pt solid; text-align: right; width: 16%" title="Loss from operations">(1,235</td> <td style="padding-bottom: 1.5pt; width: 1%">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Net loss</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td id="xdx_98C_eus-gaap--NetIncomeLoss_pn3n3_c20210101__20210331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zBxvVKiJMi02" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss">(1,099</td> <td style="padding-bottom: 2.5pt; text-align: left">)</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double">$</td> <td id="xdx_987_eus-gaap--NetIncomeLoss_pn3n3_c20200101__20200331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zuNwjsMAEk9c" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss">(1,235</td> <td style="padding-bottom: 2.5pt">)</td></tr> </table> The unaudited condensed balance sheet information of Melt is summarized below: SCHEDULE OF CONDENSED BALANCE SHEET <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; text-align: center"> At March 31,</td> <td style="padding-bottom: 1.5pt"> </td> <td> </td> <td colspan="2" style="text-align: center">At December 31,</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Current assets</td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_98F_eus-gaap--AssetsCurrent_iI_pn3n3_c20210331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_z0VyJQ3rmU8" style="width: 16%; text-align: right" title="Current assets">2,267</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td id="xdx_98B_eus-gaap--AssetsCurrent_iI_pn3n3_c20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zQ41yZJlC79f" style="text-align: right; width: 16%" title="Current assets">2,947</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Non-current assets</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td> <td id="xdx_98B_eus-gaap--AssetsNoncurrent_iI_pn3n3_c20210331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zZU50R4ycLT2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Non-current assets">79</td> <td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid"> </td> <td id="xdx_989_eus-gaap--AssetsNoncurrent_iI_pn3n3_c20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zeogpY16gX4d" style="border-bottom: Black 1.5pt solid; text-align: right" title="Non-current assets">11</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total assets</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"/> <td id="xdx_98B_eus-gaap--Assets_iI_pn3n3_c20210331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zb3QNxWp3F0g" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets">2,346</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double"> </td> <td id="xdx_980_eus-gaap--Assets_iI_pn3n3_c20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zUybk3Mc2HP1" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets">2,958</td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right" title="Current assets"> </td> <td style="text-align: left"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total liabilities</td> <td> </td> <td style="text-align: left"/> <td id="xdx_983_eus-gaap--Liabilities_iI_pn3n3_c20210331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_ziPKZt0tERA3" style="text-align: right" title="Total liabilities">2,133</td> <td style="text-align: left"> </td> <td> </td> <td> </td> <td id="xdx_98A_eus-gaap--Liabilities_iI_pn3n3_c20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zS5DTdVjPh96" style="text-align: right" title="Total liabilities">1,778</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Total stockholders equity</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td> <td id="xdx_986_eus-gaap--StockholdersEquity_iI_pn3n3_c20210331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zjWJOuprWgl9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total stockholders equity">213</td> <td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid"> </td> <td id="xdx_988_eus-gaap--StockholdersEquity_iI_pn3n3_c20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_ziVwyjiXT5il" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total stockholders equity">1,180</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total liabilities and stockholders’ equity</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td id="xdx_98C_eus-gaap--LiabilitiesAndStockholdersEquity_iI_pn3n3_c20210331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zUKUmHP0ZxV" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities and stockholder' equity">2,346</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double">$</td> <td id="xdx_981_eus-gaap--LiabilitiesAndStockholdersEquity_iI_pn3n3_c20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zPNyzll3280e" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities and stockholders' equity">2,958</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

10000

881000

851000

The unaudited condensed results of operations information of Melt is summarized below: SCHEDULE OF CONDENSED INCOME STATEMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td> <td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center">For the Three Months Ended </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: center" title="Revenues, net">March 31, 2021</td> <td style="text-align: left"> </td> <td> </td> <td colspan="2" style="text-align: center">March 31, 2020</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Revenues, net</td> <td> </td> <td style="text-align: left">$</td> <td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20210331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zBATsNPPXkvl" style="text-align: right" title="Revenues, net">-</td> <td style="text-align: left"> </td> <td> </td> <td>$</td> <td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20200331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zQn46EizSQi1" style="text-align: right" title="Revenues, net">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left; padding-bottom: 1.5pt">Loss from operations</td> <td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td> <td id="xdx_98F_eus-gaap--OperatingIncomeLoss_pn3n3_c20210101__20210331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zhR3QPNYaRCe" style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right" title="Loss from operations">(1,099</td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td> <td style="padding-bottom: 1.5pt; width: 2%"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%"> </td> <td id="xdx_984_eus-gaap--OperatingIncomeLoss_pn3n3_c20200101__20200331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zmIkVdjcPdDb" style="border-bottom: Black 1.5pt solid; text-align: right; width: 16%" title="Loss from operations">(1,235</td> <td style="padding-bottom: 1.5pt; width: 1%">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Net loss</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td id="xdx_98C_eus-gaap--NetIncomeLoss_pn3n3_c20210101__20210331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zBxvVKiJMi02" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss">(1,099</td> <td style="padding-bottom: 2.5pt; text-align: left">)</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double">$</td> <td id="xdx_987_eus-gaap--NetIncomeLoss_pn3n3_c20200101__20200331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zuNwjsMAEk9c" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss">(1,235</td> <td style="padding-bottom: 2.5pt">)</td></tr> </table>

-1099000

-1235000

-1099000

-1235000

The unaudited condensed balance sheet information of Melt is summarized below: SCHEDULE OF CONDENSED BALANCE SHEET <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; text-align: center"> At March 31,</td> <td style="padding-bottom: 1.5pt"> </td> <td> </td> <td colspan="2" style="text-align: center">At December 31,</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Current assets</td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_98F_eus-gaap--AssetsCurrent_iI_pn3n3_c20210331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_z0VyJQ3rmU8" style="width: 16%; text-align: right" title="Current assets">2,267</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td id="xdx_98B_eus-gaap--AssetsCurrent_iI_pn3n3_c20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zQ41yZJlC79f" style="text-align: right; width: 16%" title="Current assets">2,947</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Non-current assets</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td> <td id="xdx_98B_eus-gaap--AssetsNoncurrent_iI_pn3n3_c20210331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zZU50R4ycLT2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Non-current assets">79</td> <td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid"> </td> <td id="xdx_989_eus-gaap--AssetsNoncurrent_iI_pn3n3_c20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zeogpY16gX4d" style="border-bottom: Black 1.5pt solid; text-align: right" title="Non-current assets">11</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total assets</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"/> <td id="xdx_98B_eus-gaap--Assets_iI_pn3n3_c20210331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zb3QNxWp3F0g" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets">2,346</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double"> </td> <td id="xdx_980_eus-gaap--Assets_iI_pn3n3_c20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zUybk3Mc2HP1" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets">2,958</td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right" title="Current assets"> </td> <td style="text-align: left"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total liabilities</td> <td> </td> <td style="text-align: left"/> <td id="xdx_983_eus-gaap--Liabilities_iI_pn3n3_c20210331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_ziPKZt0tERA3" style="text-align: right" title="Total liabilities">2,133</td> <td style="text-align: left"> </td> <td> </td> <td> </td> <td id="xdx_98A_eus-gaap--Liabilities_iI_pn3n3_c20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zS5DTdVjPh96" style="text-align: right" title="Total liabilities">1,778</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Total stockholders equity</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td> <td id="xdx_986_eus-gaap--StockholdersEquity_iI_pn3n3_c20210331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zjWJOuprWgl9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total stockholders equity">213</td> <td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid"> </td> <td id="xdx_988_eus-gaap--StockholdersEquity_iI_pn3n3_c20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_ziVwyjiXT5il" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total stockholders equity">1,180</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total liabilities and stockholders’ equity</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td id="xdx_98C_eus-gaap--LiabilitiesAndStockholdersEquity_iI_pn3n3_c20210331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zUKUmHP0ZxV" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities and stockholder' equity">2,346</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double">$</td> <td id="xdx_981_eus-gaap--LiabilitiesAndStockholdersEquity_iI_pn3n3_c20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zPNyzll3280e" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities and stockholders' equity">2,958</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

2267000

2947000

79000

11000

2346000

2958000

2133000

1778000

213000

1180000

2346000

2958000

NOTE 5. INVESTMENT IN SURFACE OPHTHALMICS, INC. - RELATED PARTY TRANSACTIONS The Company entered into an asset purchase and license agreement with Surface in 2017 and amended it in April 2018 (the “Surface License Agreements”). Pursuant to the terms of the Surface License Agreements, the Company assigned and licensed to Surface certain intellectual property and related rights associated with Surface’s drug candidates (collectively, the “Surface Products”). Surface is required to make mid-single-digit royalty payments to the Company on net sales of the Surface Products while any patent rights remain outstanding. As of March 31, 2021, the Company owned 3,500,000 shares of Surface common stock (approximately <span id="xdx_90F_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pii_dp_c20210331__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_zyNBINFwBjaf" title="Equity method investment, ownership percentage">30% of the issued and outstanding equity interests). A Company director, Richard L. Lindstrom, and the Company’s Chief Executive Officer, Mark L. Baum, are directors of Surface. Surface is required to make royalty payments to Dr. Lindstrom of <span id="xdx_90A_ecustom--RoyaltyPaymentPercentageOnNetSales_pii_dp_c20200101__20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember__srt--TitleOfIndividualAxis__custom--DrLindstromMember_zkABnRuWx3F5" title="Royalty payment percentage on net sales">3% of net sales of certain Surface products while certain patent rights remain outstanding. Dr. Lindstrom is also a minority owner of Flying L Partners, an affiliate of the funding investor who purchased the Surface Series A Preferred Stock. Several employees and a director of the Company (including Mr. Baum and Dr. Lindstrom) entered into consulting agreements and provide consulting services to Surface. The unaudited condensed results of operations information of Surface is summarized below: SUMMARY OF CONDENSED INCOME STATEMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td> <td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">For the Three Months Ended</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td> <td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2021</td> <td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center">March 31, 2020</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Revenues, net</td> <td> </td> <td style="text-align: left">$</td> <td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20210331__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_z8jsNI2hJY1b" style="text-align: right" title="Revenues, net">-</td> <td style="text-align: left"> </td> <td> </td> <td>$</td> <td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20200331__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_zzdMPVZn6mU" style="text-align: right" title="Revenues, net">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left; padding-bottom: 1.5pt">Loss from operations</td> <td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--OperatingIncomeLoss_pn3n3_c20210101__20210331__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_zWsrrNxeF2D7" style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right" title="Loss from operations">(2,831</td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td> <td style="padding-bottom: 1.5pt; width: 2%"> </td> <td style="padding-bottom: 1.5pt; width: 1%"> </td> <td id="xdx_98A_eus-gaap--OperatingIncomeLoss_pn3n3_c20200101__20200331__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_z7b00BYOwJ6l" style="border-bottom: Black 1.5pt solid; text-align: right; width: 16%" title="Loss from operations">(1,131</td> <td style="padding-bottom: 1.5pt; width: 1%">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: left">Net loss</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td id="xdx_988_eus-gaap--NetIncomeLoss_pn3n3_c20210101__20210331__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_zebBGo3qMbHg" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss">(2,831</td> <td style="padding-bottom: 2.5pt; text-align: left">)</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double">$</td> <td id="xdx_983_eus-gaap--NetIncomeLoss_pn3n3_c20200101__20200331__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_z18I3GcLZb99" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss">(1,131</td> <td style="padding-bottom: 2.5pt">)</td></tr> </table> The unaudited condensed balance sheet information of Surface is summarized below: SUMMARY OF CONDENSED BALANCE SHEET <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; text-align: center"> At March 31,</td> <td style="padding-bottom: 1.5pt"> </td> <td> </td> <td colspan="2" style="text-align: center">At December 31,</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Current assets</td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_98A_eus-gaap--AssetsCurrent_iI_pn3n3_c20210331__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_zUprSVB9CUs3" style="width: 16%; text-align: right" title="Current assets">6,013</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td id="xdx_98C_eus-gaap--AssetsCurrent_iI_pn3n3_c20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_zwT8UX2cdWI5" style="text-align: right; width: 16%" title="Current assets">9,074</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Non current assets</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td> <td id="xdx_98D_eus-gaap--AssetsNoncurrent_iI_pn3n3_c20210331__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_zSe6vCKZcGM1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Non current assets">44</td> <td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid"> </td> <td id="xdx_981_eus-gaap--AssetsNoncurrent_iI_pn3n3_c20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_zP5jdlCUFlW2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Non current assets">45</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total assets</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"/> <td id="xdx_989_eus-gaap--Assets_iI_pn3n3_c20210331__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_z18bHpTANW84" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets">6,057</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double"> </td> <td id="xdx_98F_eus-gaap--Assets_iI_pn3n3_c20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_zUeGCH6eNtw8" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets">9,119</td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right" title="Current assets"> </td> <td style="text-align: left"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total liabilities</td> <td> </td> <td style="text-align: left"/> <td id="xdx_989_eus-gaap--Liabilities_iI_pn3n3_c20210331__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_zl6anc337gq9" style="text-align: right" title="Total liabilities">1,328</td> <td style="text-align: left"> </td> <td> </td> <td> </td> <td id="xdx_986_eus-gaap--Liabilities_iI_pn3n3_c20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_ztqh6tI9nPNb" style="text-align: right" title="Total liabilities">1,666</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Total stockholders equity</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td> <td id="xdx_989_eus-gaap--StockholdersEquity_iI_pn3n3_c20210331__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_zivdm1Xhm5Bh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total stockholders equity">4,729</td> <td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid"> </td> <td id="xdx_98F_eus-gaap--StockholdersEquity_iI_pn3n3_c20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_z1dpXbHR0vx5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total stockholders equity">7,453</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total liabilities and stockholders’ equity</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td id="xdx_981_eus-gaap--LiabilitiesAndStockholdersEquity_iI_pn3n3_c20210331__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_zXIg1wjgrLUe" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities and stockholders' equity">6,057</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double">$</td> <td id="xdx_983_eus-gaap--LiabilitiesAndStockholdersEquity_iI_pn3n3_c20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_zKQuVucNjXSi" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities and stockholders' equity">9,119</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table> 3500000

0.30

0.03 The unaudited condensed results of operations information of Surface is summarized below: SUMMARY OF CONDENSED INCOME STATEMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td> <td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">For the Three Months Ended</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td> <td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2021</td> <td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center">March 31, 2020</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Revenues, net</td> <td> </td> <td style="text-align: left">$</td> <td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20210331__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_z8jsNI2hJY1b" style="text-align: right" title="Revenues, net">-</td> <td style="text-align: left"> </td> <td> </td> <td>$</td> <td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20200331__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_zzdMPVZn6mU" style="text-align: right" title="Revenues, net">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left; padding-bottom: 1.5pt">Loss from operations</td> <td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--OperatingIncomeLoss_pn3n3_c20210101__20210331__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_zWsrrNxeF2D7" style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right" title="Loss from operations">(2,831</td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td> <td style="padding-bottom: 1.5pt; width: 2%"> </td> <td style="padding-bottom: 1.5pt; width: 1%"> </td> <td id="xdx_98A_eus-gaap--OperatingIncomeLoss_pn3n3_c20200101__20200331__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_z7b00BYOwJ6l" style="border-bottom: Black 1.5pt solid; text-align: right; width: 16%" title="Loss from operations">(1,131</td> <td style="padding-bottom: 1.5pt; width: 1%">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: left">Net loss</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td id="xdx_988_eus-gaap--NetIncomeLoss_pn3n3_c20210101__20210331__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_zebBGo3qMbHg" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss">(2,831</td> <td style="padding-bottom: 2.5pt; text-align: left">)</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double">$</td> <td id="xdx_983_eus-gaap--NetIncomeLoss_pn3n3_c20200101__20200331__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_z18I3GcLZb99" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss">(1,131</td> <td style="padding-bottom: 2.5pt">)</td></tr> </table>

-2831000

-1131000

-2831000

-1131000

The unaudited condensed balance sheet information of Surface is summarized below: SUMMARY OF CONDENSED BALANCE SHEET <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; text-align: center"> At March 31,</td> <td style="padding-bottom: 1.5pt"> </td> <td> </td> <td colspan="2" style="text-align: center">At December 31,</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Current assets</td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_98A_eus-gaap--AssetsCurrent_iI_pn3n3_c20210331__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_zUprSVB9CUs3" style="width: 16%; text-align: right" title="Current assets">6,013</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td id="xdx_98C_eus-gaap--AssetsCurrent_iI_pn3n3_c20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_zwT8UX2cdWI5" style="text-align: right; width: 16%" title="Current assets">9,074</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Non current assets</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td> <td id="xdx_98D_eus-gaap--AssetsNoncurrent_iI_pn3n3_c20210331__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_zSe6vCKZcGM1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Non current assets">44</td> <td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid"> </td> <td id="xdx_981_eus-gaap--AssetsNoncurrent_iI_pn3n3_c20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_zP5jdlCUFlW2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Non current assets">45</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total assets</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"/> <td id="xdx_989_eus-gaap--Assets_iI_pn3n3_c20210331__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_z18bHpTANW84" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets">6,057</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double"> </td> <td id="xdx_98F_eus-gaap--Assets_iI_pn3n3_c20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_zUeGCH6eNtw8" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets">9,119</td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right" title="Current assets"> </td> <td style="text-align: left"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total liabilities</td> <td> </td> <td style="text-align: left"/> <td id="xdx_989_eus-gaap--Liabilities_iI_pn3n3_c20210331__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_zl6anc337gq9" style="text-align: right" title="Total liabilities">1,328</td> <td style="text-align: left"> </td> <td> </td> <td> </td> <td id="xdx_986_eus-gaap--Liabilities_iI_pn3n3_c20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_ztqh6tI9nPNb" style="text-align: right" title="Total liabilities">1,666</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Total stockholders equity</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td> <td id="xdx_989_eus-gaap--StockholdersEquity_iI_pn3n3_c20210331__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_zivdm1Xhm5Bh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total stockholders equity">4,729</td> <td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid"> </td> <td id="xdx_98F_eus-gaap--StockholdersEquity_iI_pn3n3_c20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_z1dpXbHR0vx5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total stockholders equity">7,453</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total liabilities and stockholders’ equity</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td id="xdx_981_eus-gaap--LiabilitiesAndStockholdersEquity_iI_pn3n3_c20210331__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_zXIg1wjgrLUe" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities and stockholders' equity">6,057</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double">$</td> <td id="xdx_983_eus-gaap--LiabilitiesAndStockholdersEquity_iI_pn3n3_c20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_zKQuVucNjXSi" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities and stockholders' equity">9,119</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

6013000

9074000

44000

45000

6057000

9119000

1328000

1666000

4729000

7453000

6057000

9119000

NOTE 6. RESTRICTED CASH The restricted cash at March 31, 2021 and December 31, 2020 consisted of funds held in a money market account. At March 31, 2021 and December 31, 2020, the restricted cash was recorded at amortized cost, which approximates fair value. At March 31, 2021 and December 31, 2020, the funds held in a money market account of $200 were classified as a current asset. The money market account funds are required as collateral as additional security for the Company’s New Jersey facility lease.

200000

NOTE 7. INVENTORIES Inventories are comprised of finished compounded formulations, over-the-counter and prescription retail pharmacy products, commercial pharmaceutical products, related laboratory supplies and active pharmaceutical ingredients. The composition of inventories as of March 31, 2021 and December 31, 2020 was as follows: SCHEDULE OF INVENTORIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_499_20210331_zDBQdUiRY2n6" style="border-bottom: Black 1.5pt solid; text-align: center">March 31, 2021</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20201231_zio3QaGPmPj8" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2020</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40B_eus-gaap--InventoryRawMaterials_iI_maCzD86_zRricTRwzaC9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 58%; text-align: left">Raw materials</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 18%; text-align: right">2,512</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 18%; text-align: right">2,501</td> <td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--InventoryWorkInProcess_iI_maCzD86_zdCgmguUlAlc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Work in progress</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">3</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">17</td> <td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--InventoryFinishedGoods_iI_maCzD86_z0LTBUAkgFq7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Finished goods</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right">1,981</td> <td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right">1,444</td> <td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--InventoryNet_iTI_mtCzD86_z4QkhmASGZaj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total inventories</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">4,496</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">3,962</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

Inventories are comprised of finished compounded formulations, over-the-counter and prescription retail pharmacy products, commercial pharmaceutical products, related laboratory supplies and active pharmaceutical ingredients. The composition of inventories as of March 31, 2021 and December 31, 2020 was as follows: SCHEDULE OF INVENTORIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_499_20210331_zDBQdUiRY2n6" style="border-bottom: Black 1.5pt solid; text-align: center">March 31, 2021</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20201231_zio3QaGPmPj8" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2020</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40B_eus-gaap--InventoryRawMaterials_iI_maCzD86_zRricTRwzaC9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 58%; text-align: left">Raw materials</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 18%; text-align: right">2,512</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 18%; text-align: right">2,501</td> <td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--InventoryWorkInProcess_iI_maCzD86_zdCgmguUlAlc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Work in progress</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">3</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">17</td> <td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--InventoryFinishedGoods_iI_maCzD86_z0LTBUAkgFq7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Finished goods</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right">1,981</td> <td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right">1,444</td> <td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--InventoryNet_iTI_mtCzD86_z4QkhmASGZaj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total inventories</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">4,496</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">3,962</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

2512000

2501000

3000

17000

1981000

1444000

4496000

3962000

NOTE 8. PREPAID EXPENSES AND OTHER CURRENT ASSETS Prepaid expenses and other current assets at March 31, 2021 and December 31, 2020, consisted of the following: SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20210331_zR9hp5lJjW7g" style="border-bottom: Black 1.5pt solid; text-align: center">March 31, 2021</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20201231_zdh0TfMKQMF" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2020</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_401_eus-gaap--PrepaidInsurance_iI_zwG07MUdL3Pa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 58%; text-align: left">Prepaid insurance</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 18%; text-align: right">171</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 18%; text-align: right">160</td> <td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--OtherPrepaidExpenseCurrent_iI_zBJOW7oZhob8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other prepaid expenses</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">399</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">401</td> <td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--OtherAssetsCurrent_iI_zrjWODEOK2d" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Deposits and other current assets</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right">193</td> <td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right">190</td> <td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--PrepaidExpenseAndOtherAssetsCurrent1_iI_z3EjiuXDO1Vb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total prepaid expenses and other current assets</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">763</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">751</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

Prepaid expenses and other current assets at March 31, 2021 and December 31, 2020, consisted of the following: SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20210331_zR9hp5lJjW7g" style="border-bottom: Black 1.5pt solid; text-align: center">March 31, 2021</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20201231_zdh0TfMKQMF" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2020</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_401_eus-gaap--PrepaidInsurance_iI_zwG07MUdL3Pa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 58%; text-align: left">Prepaid insurance</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 18%; text-align: right">171</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 18%; text-align: right">160</td> <td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--OtherPrepaidExpenseCurrent_iI_zBJOW7oZhob8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other prepaid expenses</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">399</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">401</td> <td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--OtherAssetsCurrent_iI_zrjWODEOK2d" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Deposits and other current assets</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right">193</td> <td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right">190</td> <td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--PrepaidExpenseAndOtherAssetsCurrent1_iI_z3EjiuXDO1Vb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total prepaid expenses and other current assets</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">763</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">751</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

171000

160000

399000

401000

193000

190000

763000 751000

NOTE 9. PROPERTY, PLANT AND EQUIPMENT Property, plant and equipment at March 31, 2021 and December 31, 2020, consisted of the following: SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20210331_zO3lCoGsxVba" style="border-bottom: Black 1.5pt solid; text-align: center">March 31, 2021</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_499_20201231_zRfxudiWYmQi" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2020</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Property, plant and equipment, net:</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--CapitalizedComputerSoftwareGross_iI_pn3n3_maPPAEGzzle_zol732MOqNhh" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 58%; text-align: left">Computer software and hardware</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 18%; text-align: right">1,900</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 18%; text-align: right">1,707</td> <td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--FurnitureAndFixturesGross_iI_pn3n3_maPPAEGzzle_znjcl83jCv39" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Furniture and equipment</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">422</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">418</td> <td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--MachineryAndEquipmentGross_iI_pn3n3_maPPAEGzzle_zkt0g9hYYVw9" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Lab and pharmacy equipment</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">3,436</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">3,426</td> <td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LeaseholdImprovementsGross_iI_pn3n3_maPPAEGzzle_zTj4evZ4Zm81" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Leasehold improvements</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right">5,725</td> <td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right">5,720</td> <td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iTI_pn3n3_mtPPAEGzzle_maPPAENzQqn_z3P9rFI2ojR5" style="vertical-align: bottom; background-color: White"> <td>Property, plant and equipment, gross</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">11,483</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">11,271</td> <td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENzQqn_zBow8HAHzSWh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Accumulated depreciation and amortization</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right">(7,283</td> <td style="padding-bottom: 1.5pt; text-align: left">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right">(6,818</td> <td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENzQqn_ztqwbHrGRVEk" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: right; padding-bottom: 2.5pt">Property, plant and equipment, net</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">4,200</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">4,453</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> For the three months ended March 31, 2021 and 2020, depreciation and amortization related to the property, plant and equipment was $464 and $448, respectively.

Property, plant and equipment at March 31, 2021 and December 31, 2020, consisted of the following: SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20210331_zO3lCoGsxVba" style="border-bottom: Black 1.5pt solid; text-align: center">March 31, 2021</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_499_20201231_zRfxudiWYmQi" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2020</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Property, plant and equipment, net:</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--CapitalizedComputerSoftwareGross_iI_pn3n3_maPPAEGzzle_zol732MOqNhh" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 58%; text-align: left">Computer software and hardware</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 18%; text-align: right">1,900</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 18%; text-align: right">1,707</td> <td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--FurnitureAndFixturesGross_iI_pn3n3_maPPAEGzzle_znjcl83jCv39" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Furniture and equipment</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">422</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">418</td> <td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--MachineryAndEquipmentGross_iI_pn3n3_maPPAEGzzle_zkt0g9hYYVw9" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Lab and pharmacy equipment</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">3,436</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">3,426</td> <td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LeaseholdImprovementsGross_iI_pn3n3_maPPAEGzzle_zTj4evZ4Zm81" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Leasehold improvements</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right">5,725</td> <td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right">5,720</td> <td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iTI_pn3n3_mtPPAEGzzle_maPPAENzQqn_z3P9rFI2ojR5" style="vertical-align: bottom; background-color: White"> <td>Property, plant and equipment, gross</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">11,483</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">11,271</td> <td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENzQqn_zBow8HAHzSWh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Accumulated depreciation and amortization</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right">(7,283</td> <td style="padding-bottom: 1.5pt; text-align: left">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right">(6,818</td> <td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENzQqn_ztqwbHrGRVEk" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: right; padding-bottom: 2.5pt">Property, plant and equipment, net</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">4,200</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">4,453</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

1900000

1707000

422000

418000

3436000

3426000

5725000

5720000

11483000

11271000

7283000

6818000

4200000

4453000

464000

448000

NOTE 10. INTANGIBLE ASSETS AND GOODWILL The Company’s intangible assets at March 31, 2021 consisted of the following: SCHEDULE OF INTANGIBLE ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; font-size: 12pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom">Amortization periods (in years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">Cost</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">Accumulated amortization</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">Impairment</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">Net carrying value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 12pt"> </td><td style="font-size: 12pt"> </td> <td style="text-align: center; font-size: 12pt"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 20%">Patents</td><td style="width: 2%"> </td> <td style="text-align: center; width: 20%"><span id="xdx_904_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember__srt--RangeAxis__srt--MinimumMember_zlfIiSkiW74g" title="Amortization periods (in years)">17-<span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember__srt--RangeAxis__srt--MaximumMember_zqSFhEwOPCVd" title="Amortization periods (in years)">19 years</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zkLt4DFGsOie" style="width: 10%; text-align: right" title="Cost">532</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zVmbG7XeJzD3" style="width: 10%; text-align: right" title="Accumulated amortization">(54</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pn3n3_c20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zRKUD87yoZYi" style="width: 10%; text-align: right" title="Impairment">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zOClStHTQvEf" style="width: 10%; text-align: right" title="Net carrying value">478</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Licenses</td><td> </td> <td style="text-align: center"><span id="xdx_904_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zfnT8PmKCK1c" title="Amortization periods (in years)">20 years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_z7BN87KUcx64" style="text-align: right" title="Cost">50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zQyGBmiUmDyk" style="text-align: right" title="Accumulated amortization">(6</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pn3n3_c20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zTGehquJxQS1" style="text-align: right" title="Impairment">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zFgvjYevTXri" style="text-align: right" title="Net carrying value">44</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Trademarks</td><td> </td> <td style="text-align: center"><span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetsAmortizationMethod_c20210101__20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zebdmT4IytPa" title="Amortization periods description">Indefinite</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zDTidhEu0gne" style="text-align: right" title="Cost">357</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_z9Uq8sFhOCJ1" style="text-align: right" title="Accumulated amortization">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pn3n3_c20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zK0uokCxI34k" style="text-align: right" title="Impairment">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zVQmFHfKhwwl" style="text-align: right" title="Net carrying value">357</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Customer relationships</td><td> </td> <td style="text-align: center"><span id="xdx_900_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember__srt--RangeAxis__srt--MinimumMember_zT3tDo1HjNs6" title="Amortization periods (in years)">3-<span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember__srt--RangeAxis__srt--MaximumMember_zMZhxrPMdLH9" title="Amortization periods (in years)">15 years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z0xRuFFywMRl" style="text-align: right" title="Cost">1,519</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zZuyGrD0JTEl" style="text-align: right" title="Accumulated amortization">(487</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pn3n3_c20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zVmMvntUuf98" style="text-align: right" title="Impairment">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z2iwv5kiAmHg" style="text-align: right" title="Net carrying value">1,032</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Trade name</td><td> </td> <td style="text-align: center"><span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zgGlfX2MMtS5" title="Amortization periods (in years)">5 years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zQy7osPC0zl7" style="text-align: right" title="Cost">5</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zEMq0IRDOGU6" style="text-align: right" title="Accumulated amortization">(5</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pn3n3_c20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zC96YizqR2sb" style="text-align: right" title="Impairment">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_z7Hc2Utw1VIk" style="text-align: right" title="Net carrying value">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Non-competition clause</td><td> </td> <td style="text-align: center"><span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember__srt--RangeAxis__srt--MinimumMember_zTKy8wrjzy0d" title="Amortization periods (in years)">3-<span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember__srt--RangeAxis__srt--MaximumMember_zZ3uEGXMeXol" title="Amortization periods (in years)">4 years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_z2N5jYObaUY9" style="text-align: right" title="Cost">50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_z45aBI0Eohj3" style="text-align: right" title="Accumulated amortization">(50</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pn3n3_c20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_z57Llnkgbl42" style="text-align: right" title="Impairment">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zPbHfmVt8jU2" style="text-align: right" title="Net carrying value">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; text-align: left">State pharmacy licenses</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt"><span id="xdx_904_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zGIi5HVZy3Kb" title="Amortization periods (in years)">25 years</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zypMGL3hDYV3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost">8</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zsOPT3kunry2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated amortization">(7</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pn3n3_c20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zmjO8iOfEGzg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Impairment">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zVvAj7OF3eSa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net carrying value">1</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20210331_zm1wUtCYULt4" style="border-bottom: Black 2.5pt double; text-align: right" title="Cost">2,521</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20210331_zFVvtdsZnVid" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated amortization">(609</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pn3n3_c20210331_znbC9SWKNB8d" style="border-bottom: Black 2.5pt double; text-align: right" title="Impairment">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20210331_zf3Sl9UazgO1" style="border-bottom: Black 2.5pt double; text-align: right" title="Net carrying value">1,912</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Amortization expense for intangible assets for the three months ended March 31, 2021 and 2020 was as follows: SCHEDULE OF AMORTIZATION EXPENSES FOR INTANGIBLE ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">For the Three Months Ended March 31,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%">Patents</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20210101__20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zr2A5UdNxsj6" style="width: 18%; text-align: right" title="Amortization of intangible assets">6</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20200101__20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_za4JsRU6xkxk" style="width: 18%; text-align: right" title="Amortization of intangible assets">11</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Licenses</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20210101__20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_z79LD04Qa429" style="text-align: right" title="Amortization of intangible assets">1</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20200101__20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zeqGq1PHBjrj" style="text-align: right" title="Amortization of intangible assets">1</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Customer relationships</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20210101__20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zRM0bLVSgk34" style="text-align: right" title="Amortization of intangible assets">33</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20200101__20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zow1nXbUFLZ8" style="text-align: right" title="Amortization of intangible assets">33</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Trade name</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20210101__20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_z3bLnElbvg2h" style="text-align: right" title="Amortization of intangible assets">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20200101__20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_ze5t9zno9Pu4" style="text-align: right" title="Amortization of intangible assets">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">State pharmacy licenses</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20210101__20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zSqaptIibjjj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization of intangible assets">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20200101__20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zXEDBm5X8o0f" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization of intangible assets">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20210101__20210331_z5dOFVhU0sbj" style="border-bottom: Black 2.5pt double; text-align: right" title="Amortization of intangible assets">40</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20200101__20200331_z9xqfrBjJQgc" style="border-bottom: Black 2.5pt double; text-align: right" title="Amortization of intangible assets">45</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Estimated future amortization expense for the Company’s intangible assets at March 31, 2021 is as follows: SCHEDULE OF ESTIMATED FUTURE AMORTIZATION EXPENSE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49C_20210331_z6jUQ3Cdyi7j" style="text-align: right">2021</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_pn3n3_maFLIANz1kz_maFLIANz9py_maFLIANz6Td_zv9CpPXkGiL6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%">Remainder of 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">149</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_maFLIANz1kz_maFLIANz9py_maFLIANz6Td_zD8l0ygQrWp6" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: middle; text-align: left">2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">188</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pn3n3_maFLIANz1kz_maFLIANz9py_maFLIANz6Td_zjKctwyWe3zh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: middle; text-align: left">2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">188</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pn3n3_maFLIANz1kz_maFLIANz9py_maFLIANz6Td_zKaGHBRjXd9" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: middle; text-align: left">2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">161</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pn3n3_maFLIANz1kz_maFLIANz9py_maFLIANz6Td_zv0my6KuJLOa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: middle; text-align: left">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">148</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_pn3n3_maFLIANz1kz_maFLIANz9py_maFLIANz6Td_znqpH3O9yyt9" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">721</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pn3n3_mtFLIANz6Td_zL1E3f0VWw99" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Intangible assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,555</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

The Company’s intangible assets at March 31, 2021 consisted of the following: SCHEDULE OF INTANGIBLE ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; font-size: 12pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom">Amortization periods (in years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">Cost</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">Accumulated amortization</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">Impairment</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">Net carrying value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 12pt"> </td><td style="font-size: 12pt"> </td> <td style="text-align: center; font-size: 12pt"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 20%">Patents</td><td style="width: 2%"> </td> <td style="text-align: center; width: 20%"><span id="xdx_904_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember__srt--RangeAxis__srt--MinimumMember_zlfIiSkiW74g" title="Amortization periods (in years)">17-<span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember__srt--RangeAxis__srt--MaximumMember_zqSFhEwOPCVd" title="Amortization periods (in years)">19 years</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zkLt4DFGsOie" style="width: 10%; text-align: right" title="Cost">532</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zVmbG7XeJzD3" style="width: 10%; text-align: right" title="Accumulated amortization">(54</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pn3n3_c20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zRKUD87yoZYi" style="width: 10%; text-align: right" title="Impairment">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zOClStHTQvEf" style="width: 10%; text-align: right" title="Net carrying value">478</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Licenses</td><td> </td> <td style="text-align: center"><span id="xdx_904_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zfnT8PmKCK1c" title="Amortization periods (in years)">20 years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_z7BN87KUcx64" style="text-align: right" title="Cost">50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zQyGBmiUmDyk" style="text-align: right" title="Accumulated amortization">(6</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pn3n3_c20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zTGehquJxQS1" style="text-align: right" title="Impairment">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zFgvjYevTXri" style="text-align: right" title="Net carrying value">44</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Trademarks</td><td> </td> <td style="text-align: center"><span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetsAmortizationMethod_c20210101__20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zebdmT4IytPa" title="Amortization periods description">Indefinite</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zDTidhEu0gne" style="text-align: right" title="Cost">357</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_z9Uq8sFhOCJ1" style="text-align: right" title="Accumulated amortization">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pn3n3_c20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zK0uokCxI34k" style="text-align: right" title="Impairment">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zVQmFHfKhwwl" style="text-align: right" title="Net carrying value">357</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Customer relationships</td><td> </td> <td style="text-align: center"><span id="xdx_900_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember__srt--RangeAxis__srt--MinimumMember_zT3tDo1HjNs6" title="Amortization periods (in years)">3-<span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember__srt--RangeAxis__srt--MaximumMember_zMZhxrPMdLH9" title="Amortization periods (in years)">15 years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z0xRuFFywMRl" style="text-align: right" title="Cost">1,519</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zZuyGrD0JTEl" style="text-align: right" title="Accumulated amortization">(487</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pn3n3_c20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zVmMvntUuf98" style="text-align: right" title="Impairment">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z2iwv5kiAmHg" style="text-align: right" title="Net carrying value">1,032</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Trade name</td><td> </td> <td style="text-align: center"><span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zgGlfX2MMtS5" title="Amortization periods (in years)">5 years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zQy7osPC0zl7" style="text-align: right" title="Cost">5</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zEMq0IRDOGU6" style="text-align: right" title="Accumulated amortization">(5</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pn3n3_c20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zC96YizqR2sb" style="text-align: right" title="Impairment">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_z7Hc2Utw1VIk" style="text-align: right" title="Net carrying value">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Non-competition clause</td><td> </td> <td style="text-align: center"><span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember__srt--RangeAxis__srt--MinimumMember_zTKy8wrjzy0d" title="Amortization periods (in years)">3-<span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember__srt--RangeAxis__srt--MaximumMember_zZ3uEGXMeXol" title="Amortization periods (in years)">4 years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_z2N5jYObaUY9" style="text-align: right" title="Cost">50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_z45aBI0Eohj3" style="text-align: right" title="Accumulated amortization">(50</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pn3n3_c20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_z57Llnkgbl42" style="text-align: right" title="Impairment">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zPbHfmVt8jU2" style="text-align: right" title="Net carrying value">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; text-align: left">State pharmacy licenses</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt"><span id="xdx_904_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zGIi5HVZy3Kb" title="Amortization periods (in years)">25 years</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zypMGL3hDYV3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost">8</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zsOPT3kunry2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated amortization">(7</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pn3n3_c20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zmjO8iOfEGzg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Impairment">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zVvAj7OF3eSa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net carrying value">1</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20210331_zm1wUtCYULt4" style="border-bottom: Black 2.5pt double; text-align: right" title="Cost">2,521</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20210331_zFVvtdsZnVid" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated amortization">(609</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pn3n3_c20210331_znbC9SWKNB8d" style="border-bottom: Black 2.5pt double; text-align: right" title="Impairment">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20210331_zf3Sl9UazgO1" style="border-bottom: Black 2.5pt double; text-align: right" title="Net carrying value">1,912</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

P17Y

P19Y

532000

-54000

478000

P20Y

50000

-6000

44000

Indefinite

357000

P3Y

P15Y

1519000

-487000

1032000

P5Y

5000

-5000

P3Y

P4Y

50000

-50000

P25Y

8000

-7000

1000

2521000

-609000

1912000

Amortization expense for intangible assets for the three months ended March 31, 2021 and 2020 was as follows: SCHEDULE OF AMORTIZATION EXPENSES FOR INTANGIBLE ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">For the Three Months Ended March 31,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%">Patents</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20210101__20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zr2A5UdNxsj6" style="width: 18%; text-align: right" title="Amortization of intangible assets">6</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20200101__20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_za4JsRU6xkxk" style="width: 18%; text-align: right" title="Amortization of intangible assets">11</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Licenses</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20210101__20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_z79LD04Qa429" style="text-align: right" title="Amortization of intangible assets">1</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20200101__20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zeqGq1PHBjrj" style="text-align: right" title="Amortization of intangible assets">1</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Customer relationships</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20210101__20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zRM0bLVSgk34" style="text-align: right" title="Amortization of intangible assets">33</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20200101__20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zow1nXbUFLZ8" style="text-align: right" title="Amortization of intangible assets">33</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Trade name</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20210101__20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_z3bLnElbvg2h" style="text-align: right" title="Amortization of intangible assets">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20200101__20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_ze5t9zno9Pu4" style="text-align: right" title="Amortization of intangible assets">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">State pharmacy licenses</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20210101__20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zSqaptIibjjj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization of intangible assets">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20200101__20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zXEDBm5X8o0f" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization of intangible assets">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20210101__20210331_z5dOFVhU0sbj" style="border-bottom: Black 2.5pt double; text-align: right" title="Amortization of intangible assets">40</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20200101__20200331_z9xqfrBjJQgc" style="border-bottom: Black 2.5pt double; text-align: right" title="Amortization of intangible assets">45</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

6000

11000

1000

33000

40000

45000

Estimated future amortization expense for the Company’s intangible assets at March 31, 2021 is as follows: SCHEDULE OF ESTIMATED FUTURE AMORTIZATION EXPENSE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49C_20210331_z6jUQ3Cdyi7j" style="text-align: right">2021</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_pn3n3_maFLIANz1kz_maFLIANz9py_maFLIANz6Td_zv9CpPXkGiL6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%">Remainder of 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">149</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_maFLIANz1kz_maFLIANz9py_maFLIANz6Td_zD8l0ygQrWp6" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: middle; text-align: left">2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">188</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pn3n3_maFLIANz1kz_maFLIANz9py_maFLIANz6Td_zjKctwyWe3zh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: middle; text-align: left">2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">188</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pn3n3_maFLIANz1kz_maFLIANz9py_maFLIANz6Td_zKaGHBRjXd9" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: middle; text-align: left">2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">161</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pn3n3_maFLIANz1kz_maFLIANz9py_maFLIANz6Td_zv0my6KuJLOa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: middle; text-align: left">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">148</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_pn3n3_maFLIANz1kz_maFLIANz9py_maFLIANz6Td_znqpH3O9yyt9" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">721</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pn3n3_mtFLIANz6Td_zL1E3f0VWw99" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Intangible assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,555</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

149000

188000

161000

148000

721000

1555000

NOTE 11. ACCOUNTS PAYABLE AND ACCRUED EXPENSES Accounts payable and accrued expenses consisted of the following: SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20210331_zZSOv94xYIGd" style="border-bottom: Black 1.5pt solid; text-align: center">March 31, 2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20201231_zEVjen3pwKcl" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_409_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_pn3n3_maAPAALzL96_zMwRPWBr1x8g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Accounts payable</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">4,941</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">3,645</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--OtherAccruedLiabilitiesCurrentAndNoncurrent_iI_pn3n3_maAPAALzL96_zm17iDOpHRHc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other accrued expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">49</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">49</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pn3n3_maAPAALzL96_zapM7H2xwhm6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accrued interest</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">186</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">238</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_pn3n3_maAPAALzL96_znGGeJ6zVYQl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Accrued exit fee for note payable</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">800</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">800</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_iTI_pn3n3_mtAPAALzL96_zxhRwfovyTL5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total accounts payable and accrued expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,976</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,732</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iNI_pn3n3_di_zFN3X9uIpnKa" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: Current portion</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,176</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,932</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--AccountsPayableAndAccruedLiabilitiesNoncurrent_iI_pn3n3_zUaG2oc1cUp5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Non-current total accrued expenses</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">800</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">800</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

Accounts payable and accrued expenses consisted of the following: SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20210331_zZSOv94xYIGd" style="border-bottom: Black 1.5pt solid; text-align: center">March 31, 2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20201231_zEVjen3pwKcl" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_409_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_pn3n3_maAPAALzL96_zMwRPWBr1x8g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Accounts payable</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">4,941</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">3,645</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--OtherAccruedLiabilitiesCurrentAndNoncurrent_iI_pn3n3_maAPAALzL96_zm17iDOpHRHc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other accrued expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">49</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">49</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pn3n3_maAPAALzL96_zapM7H2xwhm6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accrued interest</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">186</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">238</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_pn3n3_maAPAALzL96_znGGeJ6zVYQl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Accrued exit fee for note payable</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">800</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">800</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_iTI_pn3n3_mtAPAALzL96_zxhRwfovyTL5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total accounts payable and accrued expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,976</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,732</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iNI_pn3n3_di_zFN3X9uIpnKa" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: Current portion</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,176</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,932</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--AccountsPayableAndAccruedLiabilitiesNoncurrent_iI_pn3n3_zUaG2oc1cUp5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Non-current total accrued expenses</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">800</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">800</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

4941000

3645000

49000

186000

238000

800000

5976000

4732000

5176000

3932000

800000

NOTE 12. DEBT SWK Senior Note – 2017 In July 2017, the Company and several of its wholly owned subsidiaries entered into a term loan and security agreement in the principal amount of $<span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20170731__us-gaap--TypeOfArrangementAxis__custom--TermLoanAndSecurityAgreementMember__dei--LegalEntityAxis__custom--SWKFundingLLCMember_zwBm9AedDul4" title="Debt principal amount">16,000 (the “SWK Loan Agreement” or “SWK Loan”) with SWK Funding LLC and its partners (collectively, “SWK”), as lender and collateral agent. The SWK Loan Agreement was fully funded at closing with a five-year term; however, such term could be reduced to four years if certain revenue requirements were not achieved. The SWK Loan was secured by substantially all of the Company’s assets, including its intellectual property rights. The SWK Loan was subsequently amended in May 2019 and again in April 2020. The SWK Loan bore an interest rate that was equal to the three-month London Inter-Bank Offered Rate (subject to a minimum of <span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_uPure_c20170731__us-gaap--TypeOfArrangementAxis__custom--TermLoanAndSecurityAgreementMember__dei--LegalEntityAxis__custom--SWKFundingLLCMember__us-gaap--VariableRateAxis__us-gaap--LondonInterbankOfferedRateLIBORMember__srt--RangeAxis__srt--MinimumMember_zyl2g2NLGeAd" title="Debt instrument interest rate">2.00%), plus an applicable margin of <span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_uPure_c20170731__us-gaap--TypeOfArrangementAxis__custom--TermLoanAndSecurityAgreementMember__dei--LegalEntityAxis__custom--SWKFundingLLCMember__us-gaap--VariableRateAxis__us-gaap--BaseRateMember_z9VtVoUXTPP9" title="Debt instrument interest rate">10.00% (the “Margin Rate”); provided that, if, two days prior to a payment date, the Company provided SWK evidence that the <span id="xdx_90A_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20170701__20170731__us-gaap--TypeOfArrangementAxis__custom--TermLoanAndSecurityAgreementMember__dei--LegalEntityAxis__custom--SWKFundingLLCMember" title="Debt instrument interest rate description">Company has achieved a leverage ratio as of such date of less than 4.00:1:00, the Margin Rate shall equal 9.00%; and if the Company has achieved a leverage ratio as of such date of less than 3.00:1:00, the Margin Rate shall equal 7.00%. The leverage ratio means, as of any date of determination, the ratio of: (a) indebtedness as of such date to (b) EBITDA (as defined in the SWK Loan), of the Company for the immediately preceding 12-month period, adding-back (i) actual litigation expenses for the immediately preceding 12-month period, minus (ii) actual litigation expenses for the immediately preceding 3 month period multiplied by four. Subsequent to March 31, 2021, the Company completed an offering of unsecured senior notes in the aggregate principal amount of $55,000 and used a portion of the proceeds to pay off all outstanding obligations and indebtedness related to the SWK Loan (see Note 17 for additional information). Interest expense related to the SWK Loan Agreement, as amended, amounted to $509 and $560 for the three months ended March 31, 2021 and 2020, respectively, and included amortization of debt issuance costs and discount of $<span id="xdx_909_eus-gaap--AmortizationOfDebtDiscountPremium_pn3n3_c20210101__20210331__us-gaap--TypeOfArrangementAxis__custom--SWKSecondAmendmentMember_zpwcD875hBKa" title="Amortization of debt discount (premium)">96 and $<span id="xdx_90C_eus-gaap--AmortizationOfDebtDiscountPremium_pn3n3_c20200101__20200331__us-gaap--TypeOfArrangementAxis__custom--SWKSecondAmendmentMember_zbcDBriSu537" title="Amortization of debt discount (premium)">160 for the three months ended March 31, 2021 and 2020, respectively. Paycheck Protection Program Loan In April 2020, the Company entered into an unsecured promissory note and related Business Loan Agreement with Renasant Bank, as lender, for a loan (the “PPP Loan”) in the principal amount of $1,967 and received cash proceeds of the same amount, pursuant to the Paycheck Protection Program (the “PPP”) under the Federal Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”), which was enacted March 27, 2020. The PPP is administered by the U.S. Small Business Administration (the “SBA”). On March 30, 2021, the Company received a notice of forgiveness of the full balance of the PPP Loan, including all accrued interest, in accordance with the terms and conditions of the CARES Act. Related to the forgiveness, the Company recorded a gain on the forgiveness of debt for the loan balance of $1,967 in the accompanying condensed consolidated statement of operations for the period ended March 31, 2021. At March 31, 2021, future minimum payments under the Company’s debt were as follows: SUMMARY OF FUTURE MINIMUM PAYMENTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_499_20210331_zNFWiI2hcXz2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_404_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_iI_maCzDLz_zTrZSk009tCa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify">Remainder of 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">3,395</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_maCzDLz_z34crPiCOaD1" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,966</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_maCzDLz_z19LVbzfwGbi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">2023</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,511</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LongTermDebt_iTI_mtCzDLz_maDICAzSiD_zCKdC5KOqoAh" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Total minimum payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">16,872</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--InterestPayableCurrent_iNI_di_maDICAzSiD_zZ6n7NTOX6nk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Less: amount representing interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,511</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--DebtInstrumentCarryingAmount_iI_zK2ZB5VNU0ze" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Notes payable, gross</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">14,361</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_di_msNPz9Wo_zzjudgGdsh5e" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Less: unamortized discount</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(706</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--NotesPayable_iI_zFC32qU8Llba" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Notes payable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13,655</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--NotesPayableCurrent1_iI_zmtya4pLdBbl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Less: current portion, net of unamortized discount</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,659</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40B_ecustom--LongTermNotesPayable1_iI_zGSvK0H8L7u5" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Note payable, net of current portion and unamortized debt discount</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,996</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

16000000

0.0200

0.1000

Company has achieved a leverage ratio as of such date of less than 4.00:1:00, the Margin Rate shall equal 9.00%; and if the Company has achieved a leverage ratio as of such date of less than 3.00:1:00, the Margin Rate shall equal 7.00%.

55000000

509000

560000

96000

160000

1967000

At March 31, 2021, future minimum payments under the Company’s debt were as follows: SUMMARY OF FUTURE MINIMUM PAYMENTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_499_20210331_zNFWiI2hcXz2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_404_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_iI_maCzDLz_zTrZSk009tCa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify">Remainder of 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">3,395</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_maCzDLz_z34crPiCOaD1" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,966</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_maCzDLz_z19LVbzfwGbi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">2023</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,511</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LongTermDebt_iTI_mtCzDLz_maDICAzSiD_zCKdC5KOqoAh" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Total minimum payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">16,872</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--InterestPayableCurrent_iNI_di_maDICAzSiD_zZ6n7NTOX6nk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Less: amount representing interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,511</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--DebtInstrumentCarryingAmount_iI_zK2ZB5VNU0ze" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Notes payable, gross</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">14,361</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_di_msNPz9Wo_zzjudgGdsh5e" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Less: unamortized discount</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(706</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--NotesPayable_iI_zFC32qU8Llba" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Notes payable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13,655</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--NotesPayableCurrent1_iI_zmtya4pLdBbl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Less: current portion, net of unamortized discount</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,659</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40B_ecustom--LongTermNotesPayable1_iI_zGSvK0H8L7u5" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Note payable, net of current portion and unamortized debt discount</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,996</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

3395000

3966000

9511000

16872000

2511000

14361000

706000

13655000

-2659000 10996000

NOTE 13. LEASES The Company leases office and laboratory space under non-cancelable operating leases listed below. These lease agreements have remaining terms between one to four years and contain various clauses for renewal at the Company’s option. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">An operating lease for 10,200 square feet of office space in San Diego, California that expires in December 2021, with an option to extend the term for a five-year period;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">An operating lease for 26,400 square feet of lab, warehouse and office space in Ledgewood, New Jersey that expires in July 2026, with an option to extend the term for two additional five-year periods. This includes an amendment that was made effective July 2020 that extended the term of the original lease and added <span id="xdx_90F_eus-gaap--AreaOfLand_iI_pii_uSqft_c20210331__us-gaap--LeaseContractualTermAxis__custom--AdditionalSquareFootageOfLeaseMember__srt--StatementGeographicalAxis__custom--LedgewoodMember_z0f3Qd141tG" title="Operating lease space">1,400 of additional square footage to the lease; and</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">An operating lease for 5,500 square feet of office space in Nashville, Tennessee that expires in December 2024, with an option to extend the term for two additional five-year periods.</td></tr> </table> Future lease payments under operating leases as of March 31, 2021 were as follows: SCHEDULE OF FUTURE LEASE PAYMENTS UNDER OPERATING LEASES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20210331_zSdn8sJieai9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Operating Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maCzwE6_zAsvYJTWOUDh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%">Remainder of 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">766</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maCzwE6_z2fAYy7TG5o5" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: middle; text-align: left">2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,038</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maCzwE6_zx6mLyaoGx0g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: middle; text-align: left">2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,064</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maCzwE6_zRFkxGToTqze" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: middle; text-align: left">2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,090</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maCzwE6_z4kL318SNu1j" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: middle; text-align: left">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">916</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_maCzwE6_z3Pa14pUFF9g" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,141</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtCzwE6_maOLLzqPK_zE4JtgRznrdi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total minimum lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,015</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_maOLLzqPK_zyKn02QPtbZ2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: amount representing interest payments</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,922</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--OperatingLeaseLiability_iI_zCjkdC7ErHe8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Total operating lease liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,093</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_di_zXkT3a8lgLB2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: current portion, operating lease liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(597</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_z6MBElVckHnl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Operating lease liabilities, net of current portion</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,496</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> At March 31, 2021, the weighted-average discount rate and the weighted-average remaining lease term for the operating leases held by the Company were 6.33% and 11.02 years, respectively. During the three months ended March 31, 2021 and 2020, cash paid for amounts included for the operating lease liabilities was $251 and $271, respectively, and the Company recorded operating lease expense of $261 and $278, respectively, included in selling, general and administrative expenses. The Company also has a finance lease that is included in its lease accounting but is not considered significant. Future lease payments under the non-cancelable finance lease as of March 31, 2021 were as follows: SCHEDULE OF FUTURE LEASE PAYMENTS UNDER FINANCE LEASE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20210331_z9UPqpWUCyD9" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Finance Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_406_eus-gaap--FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maCzhS8_zZ0pqVNVNqdj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%">Remainder of 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">7</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maCzhS8_zBsFsQGLk683" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: middle; text-align: left">2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_maCzhS8_z2S0UqZ2gzme" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: middle; text-align: left">2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iI_maCzhS8_zM16EcoMEnud" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: middle; text-align: left; padding-bottom: 1.5pt">2024</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iTI_mtCzhS8_z77bhLOlyjM6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total minimum lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">26</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNI_di_zcYgYSBoL6lj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: amount representing interest payments</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--FinanceLeaseLiability_iI_zZWvLKgwlZkg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Present value of future minimum lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">24</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--FinanceLeaseLiabilityCurrent_iNI_di_zIuaNpJweB1j" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: current portion, finance lease obligation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(8</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_zuNeKA1SXsB" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Finance lease obligation, net of current portion</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">16</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> At March 31, 2021, the weighted average incremental borrowing rate and the weighted average remaining lease term for the finance lease held by the Company were 6.36% and 2.83 years, respectively. For the three months ended March 31, 2021, depreciation expense related to the equipment held under the finance lease obligation was $<span id="xdx_900_eus-gaap--OperatingLeasesIncomeStatementDepreciationExpenseOnPropertySubjectToOrHeldForLease_pn3n3_c20210101__20210331_zcYoHKyE6iih" title="Operating leases, income statement, depreciation expense on property subject to or held-for-lease">2. For the three months ended March 31, 2021, cash paid and expense recognized for interest expense related to the finance lease obligation was $1.

10200

December 2021

term for a five-year period

26400

July 2026

term for two additional five-year periods

1400

5500

December 2024

term for two additional five-year periods

Future lease payments under operating leases as of March 31, 2021 were as follows: SCHEDULE OF FUTURE LEASE PAYMENTS UNDER OPERATING LEASES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20210331_zSdn8sJieai9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Operating Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maCzwE6_zAsvYJTWOUDh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%">Remainder of 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">766</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maCzwE6_z2fAYy7TG5o5" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: middle; text-align: left">2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,038</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maCzwE6_zx6mLyaoGx0g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: middle; text-align: left">2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,064</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maCzwE6_zRFkxGToTqze" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: middle; text-align: left">2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,090</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maCzwE6_z4kL318SNu1j" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: middle; text-align: left">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">916</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_maCzwE6_z3Pa14pUFF9g" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,141</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtCzwE6_maOLLzqPK_zE4JtgRznrdi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total minimum lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,015</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_maOLLzqPK_zyKn02QPtbZ2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: amount representing interest payments</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,922</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--OperatingLeaseLiability_iI_zCjkdC7ErHe8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Total operating lease liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,093</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_di_zXkT3a8lgLB2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: current portion, operating lease liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(597</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_z6MBElVckHnl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Operating lease liabilities, net of current portion</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,496</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

766000

1038000

1064000

1090000

916000

5141000

10015000

2922000

7093000

597000

6496000

0.0633

P11Y7D

251000 271000

261000

278000

Future lease payments under the non-cancelable finance lease as of March 31, 2021 were as follows: SCHEDULE OF FUTURE LEASE PAYMENTS UNDER FINANCE LEASE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20210331_z9UPqpWUCyD9" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Finance Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_406_eus-gaap--FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maCzhS8_zZ0pqVNVNqdj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%">Remainder of 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">7</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maCzhS8_zBsFsQGLk683" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: middle; text-align: left">2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_maCzhS8_z2S0UqZ2gzme" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: middle; text-align: left">2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iI_maCzhS8_zM16EcoMEnud" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: middle; text-align: left; padding-bottom: 1.5pt">2024</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iTI_mtCzhS8_z77bhLOlyjM6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total minimum lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">26</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNI_di_zcYgYSBoL6lj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: amount representing interest payments</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--FinanceLeaseLiability_iI_zZWvLKgwlZkg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Present value of future minimum lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">24</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--FinanceLeaseLiabilityCurrent_iNI_di_zIuaNpJweB1j" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: current portion, finance lease obligation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(8</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_zuNeKA1SXsB" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Finance lease obligation, net of current portion</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">16</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

7000

9000

1000

26000

2000

24000

8000

16000

0.0636

P2Y9M29D

2000

1000

NOTE 14. STOCKHOLDERS’ EQUITY AND STOCK-BASED COMPENSATION Common Stock During the three months ended March 31, 2021, the Company issued 11,301 shares of its common stock upon the exercise of options to purchase <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pii_c20210301__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ztUBst0iehLj" title="Number of options to purchase common stock">11,301 shares of common stock, with exercise prices ranging between $<span id="xdx_90E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pii_c20210301__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXsyMhK5gtfc" title="Exercise price, minimum">1.70 to $<span id="xdx_90C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pii_c20210301__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zmYGUbz7ldN3" title="Exercise price, maximum">3.96 per share and received net proceeds of $27. During the three months ended March 31, 2021, the Company issued <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pii_c20210101__20210331__srt--TitleOfIndividualAxis__custom--MarkLBaumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zmwNaRUhNHkg" title="Number of shares isssued">200,000 shares of its common stock to Mark L. Baum, its CEO, related to the vesting of <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pii_c20210101__20210331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--MarkLBaumMember_zvKVYNd3Oz6c" title="Shares issued of restricted common stock, shares">200,000 performance-based restricted stock units. During the three months ended March 31, 2021, the Company issued <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pii_c20210101__20210331__srt--TitleOfIndividualAxis__custom--AndrewRBollMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zo6lToLU46bl" title="Number of shares isssued">22,500 shares of common stock to Andrew R. Boll, its CFO, related to the vesting of <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pii_c20210101__20210331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--AndrewRBollMember_zqfZ5erfjsUb" title="Shares issued of restricted common stock, shares">30,000 performance-based restricted stock units. The Company withheld issuance of <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesOther_pii_c20210101__20210331__srt--TitleOfIndividualAxis__custom--AndrewRBollMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zDccuUZF9Hie" title="Number of stock withheld for payroll tax purposes">7,500 shares of common stock to Mr. Boll for payroll tax purposes valued at $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueOther_pn3n3_c20210101__20210331__srt--TitleOfIndividualAxis__custom--AndrewRBollMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z0CqiTq5MkJg" title="Value of stock withheld for payroll tax purposes">57. During the three months ended March 31, 2021, <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pii_c20210101__20210331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zwdnGA8Db8ag" title="Number of shares isssued">22,755 shares of the Company’s common stock underlying RSUs issued to directors vested, but the issuance and delivery of these shares are deferred until the director resigns. Preferred Stock At March 31, 2021 and 2020, the Company had 5,000,000 shares of preferred stock, $0.001 par value, authorized and no shares of preferred stock issued and outstanding. Subsequent to March 31, 2021, the Company sold <span id="xdx_90A_eus-gaap--PreferredStockSharesIssued_iI_c20210511__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCCumulativePreferredStockMember_z6lIyw367sGk" title="Number of shared sold">440,000 shares of Series B Cumulative Preferred Stock for gross proceeds of $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_pp0p0_c20210401__20210511__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCCumulativePreferredStockMember_z0kdsOPLy408" title="Gross proceeds from stock issued">11,000 (see Note 17 for additional information). Stock Option Plan On September 17, 2007, the Company’s Board of Directors and stockholders adopted the Company’s 2007 Incentive Stock and Awards Plan, which was subsequently amended on November 5, 2008, February 26, 2012, July 18, 2012, May 2, 2013 and September 27, 2013 (as amended, the “2007 Plan”). The 2007 Plan reached its term in September 2017, and we can no longer issue additional awards under this plan, however, options previously issued under the 2007 Plan will remain outstanding until they are exercised, reach their maturity or are otherwise cancelled/forfeited. On June 13, 2017, the Company’s Board of Directors and stockholders adopted the Company’s 2017 Incentive Stock and Awards Plan (the “2017 Plan” together with the 2007 Plan, the “Plans”). As of March 31, 2021, the 2017 Plan provides for the issuance of a maximum of <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pii_c20210331__us-gaap--PlanNameAxis__custom--TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember_z69RuDhOmpae" title="Maximum number of common stock issuance under the plan">2,000,000 shares of the Company’s common stock. The purpose of the Plans are to attract and retain directors, officers, consultants, advisors and employees whose services are considered valuable, to encourage a sense of proprietorship and to stimulate an active interest of such persons in the Company’s development and financial success. Under the Plans, the Company is authorized to issue incentive stock options intended to qualify under Section 422 of the Internal Revenue Code, non-qualified stock options, restricted stock units and restricted stock. The Plans are administered by the Compensation Committee of the Company’s Board of Directors. The Company had <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pii_c20210331__us-gaap--PlanNameAxis__custom--TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember_zr5d95oEv2b8" title="Shares available for future issuances">4,077 shares available for future issuances under the 2017 Plan at March 31, 2021. Stock Options A summary of stock option activity under the Plans for the three months ended March 31, 2021 is as follows: SCHEDULE OF STOCK OPTION PLAN ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Avg. Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Avg. Remaining Contractual Life</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Options outstanding - January 1, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_c20210101__20210331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zQBmc4kMwVhg" style="width: 11%; text-align: right" title="Number of shares, Outstanding, Beginning balance">3,030,033</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20210101__20210331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zWRQg02wE7F1" style="width: 11%; text-align: right" title="Weighted Avg. Exercise Price, Outstanding, Beginning balance">5.43</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Options granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pii_c20210101__20210331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zLztR25tfFnc" style="text-align: right" title="Number of shares, Options granted">67,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20210331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_pii" style="text-align: right" title="Weighted Avg. Exercise Price, Options granted">8.07</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Options exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pii_di_c20210101__20210331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zvDyFrjOrgYi" style="text-align: right" title="Number of shares, Options exercised">(11,301</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20210101__20210331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_pii" style="text-align: right" title="Weighted Avg. Exercise Price, Options exercised">2.42</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Options cancelled/forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pii_di_c20210101__20210331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_ztoBQ3zKa037" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, Options cancelled/forfeited">(28,195</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20210331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_pii" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Avg. Exercise Price, Options cancelled/forfeited">5.45</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Options outstanding - March 31, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pii_c20210101__20210331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zGacMeQIYEmj" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, Outstanding, Ending balance">3,057,537</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pii_c20210101__20210331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zD7XP8mJSJOa" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Avg. Exercise Price, Outstanding, Ending balance">5.50</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20210331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zfWG2FhnyP39" title="Weighted Avg. Remaining Contractual Life, Options outstanding">5.54</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20210101__20210331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_z4wlC3O4fHN2" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate Intrinsic Value, Options outstanding">5,287</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Options exercisable</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pii_c20210101__20210331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zV2gtcj2pvhk" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, Options exercisable">2,169,441</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pii_c20210101__20210331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zidNlqyLJ5Cl" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Avg. Exercise Price, Exercisable Ending Balance">4.85</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210101__20210331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_z52T4ZJfhmHa" title="Weighted Avg. Remaining Contractual Life, Options exercisable">5.04</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pn3n3_c20210101__20210331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zKr96ZcOxQMe" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate Intrinsic Value, Options exercisable">4,944</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Options vested and expected to vest</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pii_c20210101__20210331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zOjjT6S9MTk6" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, Options vested and expected to vest">2,968,979</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pii_c20210101__20210331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zUDVBi33bK69" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Avg. Exercise Price, Vested and expected to vest">5.45</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210101__20210331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zGmY9NUZ0vu4" title="Weighted Avg. Remaining Contractual Life, Options vested and expected to vest">5.50</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pn3n3_c20210101__20210331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zalPGT9Krra8" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate Intrinsic Value, Options vested and expected to vest">5,254</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The aggregate intrinsic value in the table above represents the total pre-tax amount of the proceeds, net of exercise price, which would have been received by option holders if all option holders had exercised and immediately sold all options with an exercise price lower than the market price on March 31, 2021, based on the closing price of the Company’s common stock of $6.75 on that date. During the three months ended March 31, 2021, the Company granted stock options to certain employees and a consultant. The stock options were granted with an exercise price equal to the current market price of the Company’s common stock, as reported by the securities exchange on which the common stock was then listed, at the grant date and have contractual terms of <span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20200101__20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember__srt--TitleOfIndividualAxis__custom--EmployeesAndConsultantMember_z370HlHwFzZ6">10 years. <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms_c20210101__20210331__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember__srt--TitleOfIndividualAxis__custom--EmployeesAndConsultantMember_zaeR6yL8oBV6" title="Share-based compensation arrangement by share-based payment award, plan modification, description and terms">Vesting terms for options granted to employees and consultants during the three months ended March 31, 2021 were as follows: 25% of the shares subject to the option vest and become exercisable on the first anniversary of the grant date and the remaining 75% of the shares subject to the option vest and become exercisable quarterly in equal installments thereafter over three years. Certain option awards provide for accelerated vesting if there is a change in control (as defined in the Plans) and in the event of certain modifications to the option award agreement. The fair value of each option award is estimated on the date of grant using the Black-Scholes-Merton option pricing model. The expected term of options granted to employees and directors was determined in accordance with the “simplified approach,” as the Company has limited, relevant, historical data on employee exercises and post-vesting employment termination behavior. The expected risk-free interest rate is based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. The financial statement effect of forfeitures is estimated at the time of grant and revised, if necessary, if the actual effect differs from those estimates. For option grants to employees and directors, the Company assigns a forfeiture factor of 10%. These factors could change in the future, which would affect the determination of stock-based compensation expense in future periods. Utilizing these assumptions, the fair value is determined at the date of grant. The table below illustrates the fair value per share determined using the Black-Scholes-Merton option pricing model with the following assumptions used for valuing options granted to employees: SCHEDULE OF FAIR VALUE ASSUMPTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; font-size: 12pt"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Weighted-average fair value of options granted</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210101__20210331__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_pii" style="width: 20%; text-align: right" title="Weighted-average fair value of options granted">4.96</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected terms (in years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20210331__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zDdzrjuqv3Vb" title="Expected terms (in years)">6.11</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pii_dp_uPure_c20210101__20210331__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zfhgn5u3Wbeg" title="Expected volatility">69</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pii_dp_uPure_c20210101__20210331__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_z26PSaMYi3h4" title="Risk-free interest rate, minimum">0.39-<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pii_dp_uPure_c20210101__20210331__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zxFZio2b78w1" title="Risk-free interest rate, maximum">0.45 </td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pii_d0_c20210101__20210331__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zApsqMQGM392" style="text-align: right" title="Dividend yield">-</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zXf7tnS5gMlg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes information about stock options outstanding and exercisable at March 31, 2021: SCHEDULE OF STOCK OPTION OUTSTANDING AND EXERCISABLE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; font-size: 12pt"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">Options Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">Options Exercisable</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Range of Exercise Prices</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom">Number Outstanding</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom">Weighted Average Remaining Contractual Life in Years</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">Number Exercisable</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%">$<span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pii_c20210101__20210331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zIzxscWCvZRa" title="Range of Exercise Prices, minimum">1.47 - $<span id="xdx_902_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pii_c20210101__20210331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zvY6pucAW21e" title="Range of Exercise Prices, maximum">2.60</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pii_c20210331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zhCobX9zUge8" style="width: 9%; text-align: right" title="Number of Options Outstanding">760,318</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20210101__20210331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_z4Eu38QKf3Ld" title="Weighted Average Remaining Contractual Life in Years">5.38</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pii_c20210331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zqzJ9YryPCpg" style="width: 9%; text-align: right" title="Weighted Average Exercise Price">2.06</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pii_c20210331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zII3zPlo9uo1" style="width: 9%; text-align: right" title="Number Exercisable">750,557</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pii_c20210331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zdFOxDV09k87" style="width: 9%; text-align: right" title="Weighted Average Exercisable Exercise Price">2.06</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>$<span id="xdx_904_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pii_c20210101__20210331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zTIsBtOudiR9" title="Range of Exercise Prices, minimum">2.76 - $<span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pii_c20210101__20210331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zqIZB7Rj6qa2" title="Range of Exercise Prices, maximum">4.66</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pii_c20210331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zclDCYjrXa26" style="text-align: right" title="Number of Options Outstanding">513,628</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20210101__20210331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_znNCURnrOuD9" title="Weighted Average Remaining Contractual Life in Years">5.51</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pii_c20210331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zcQMhnHQCkE4" style="text-align: right" title="Weighted Average Exercise Price">3.98</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pii_c20210331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zSSVkTnHKzl9" style="text-align: right" title="Number Exercisable">442,498</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pii_c20210331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zpg9p6XECJ22" style="text-align: right" title="Weighted Average Exercisable Exercise Price">3.97</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>$<span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pii_c20210101__20210331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zsJU1pf2QDC3">5.49 - $<span id="xdx_909_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pii_c20210101__20210331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zINYFiSOtQ38">6.36</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pii_c20210331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zzt4RShrpL15" style="text-align: right" title="Number of Options Outstanding">470,350</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20210101__20210331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zDKruzbpDZ4g" title="Weighted Average Remaining Contractual Life in Years">6.84</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pii_c20210331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zjmQ98zCm1Ua" style="text-align: right" title="Weighted Average Exercise Price">6.12</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pii_c20210331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zS3Om2EGL1X2" style="text-align: right" title="Number Exercisable">320,023</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pii_c20210331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zDGq3eY9VmTc" style="text-align: right" title="Weighted Average Exercisable Exercise Price">6.13</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">$<span id="xdx_900_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pii_c20210101__20210331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zj3mtY0epdB1">6.64 - $<span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pii_c20210101__20210331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zP82CbYtg4ae">8.99</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pii_c20210331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_z3BaNflDpmIe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options Outstanding">1,313,241</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20210101__20210331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zmvWRUTtpGP1" title="Weighted Average Remaining Contractual Life in Years">5.18</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_983_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pii_c20210331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zWWsM9Ycxc7j" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Exercise Price">7.86</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pii_c20210331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zl3g8K7NyBdf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number Exercisable">656,363</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pii_c20210331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zBoji5f2t4Xb" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Exercisable Exercise Price">7.99</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">$1.47 - $8.99</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pii_c20210331_z6xAd5ExihJ4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options Outstanding">3,057,537</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20210101__20210331_zQ03DcxDigca" title="Weighted Average Remaining Contractual Life in Years">5.54</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_985_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pii_c20210331_zSVEN7yVJ1Bf" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Exercise Price">5.50</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pii_c20210331_zKc4Plkz5tac" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number Exercisable">2,169,441</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pii_c20210331_zkmhxPHdNUfc" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Exercisable Exercise Price">4.85</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> As of March 31, 2021, there was approximately $<span id="xdx_909_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn3n3_c20210331__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember_zhcNwYtpQu9i" title="Unrecognized compensation expense related to unvested stock options granted under the plan">2,582 of total unrecognized compensation expense related to unvested stock options granted under the Plans. That expense is expected to be recognized over the weighted-average remaining vesting period of <span id="xdx_90F_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20210101__20210331__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember_zxGRIivDW3Y7" title="Expense expected to recognize over the weighted-average remaining vesting period">4.59 years. The stock-based compensation for all stock options was $452 and $263 during the three months ended March 31, 2021 and 2020, respectively. The intrinsic value of options exercised during the three months ended March 31, 2021 was $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pn3n3_c20210101__20210331__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember_zI6ElThlqwVi" title="Intrinsic value of options exercised">63. Restricted Stock Units RSU awards are granted subject to certain vesting requirements and other restrictions, including performance and market-based vesting criteria. The grant date fair value of the RSUs, which has been determined based upon the market value of the Company’s common stock on the grant date, is expensed over the vesting period of the RSUs. During the three months ended March 31, 2021, <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pii_c20210101__20210331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zU0eRTPSauQ8" title="Shares issued of restricted common stock, shares">300,000 RSUs with a fair market value of $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_pn3n3_c20210101__20210331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zwXNidShhuk" title="Number of restrcited shares, value">2,670 were issued to certain employees; the RSUs vest in full on the third anniversary of the grant date. A summary of the Company’s RSU activity and related information for the three months ended March 31, 2021 is as follows: SCHEDULE OF RESTRICTED STOCK UNITS ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Number of RSUs</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Weighted Average Grant Date Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%">RSUs unvested - January 1, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pii_c20210101__20210331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zdRqi6cCCf73" style="width: 18%; text-align: right" title="Number of RSUs unvested, Outstanding, Beginning balance">1,601,509</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pii_c20210101__20210331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zSJlHR0n6hM3" style="width: 18%; text-align: right" title="Weighted Average Grant Date Fair Value, Beginning balance">3.14</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">RSUs granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pii_c20210101__20210331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zbhYZcRK36Jl" style="text-align: right" title="Number of RSUs granted">300,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_c20210101__20210331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zCfAOOQz4RC3" style="text-align: right" title="Weighted Average Grant Date Fair Value, RSUs granted">8.90</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">RSUs vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pii_di_c20210101__20210331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z0NDBr6Y9dR6" style="text-align: right" title="Number of RSUs vested">(252,755</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pii_c20210101__20210331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zWcNj3UPryL1" style="text-align: right" title="Weighted Average Grant Date Fair Value, RSUs vested">2.38</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">RSUs cancelled/forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_pii_d0_c20210101__20210331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z7lgV5z5bav9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of RSUs cancelled/forfeited">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pii_c20210101__20210331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zMeI0xvJzd8l" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Grant Date Fair Value, RSUs cancelled/forfeited">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">RSUs unvested at March 31, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pii_c20210101__20210331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zNgiUq1azNH1" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of RSUs unvested, Outstanding, Ending balance">1,648,754</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pii_c20210101__20210331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zHF6fyUBF9O1" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Grant Date Fair Value, Ending balance">4.30</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> As of March 31, 2021, the total unrecognized compensation expense related to unvested RSUs was approximately $<span id="xdx_90C_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn3n3_c20210331__us-gaap--AwardTypeAxis__custom--UnvestedRSUMember_zr77pSvGHskj" title="Unrecognized compensation expense related to unvested stock options granted under the plan">3,687, which is expected to be recognized over a weighted-average period of <span id="xdx_90F_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20210101__20210331__us-gaap--AwardTypeAxis__custom--UnvestedRSUMember_zrDKGaVvcjgl" title="Weighted-average period for recognition">0.82 years, based on estimated and actual vesting schedules of the applicable RSUs. The stock-based compensation for RSUs during the three months ended March 31, 2021 and 2020 was $346 and $259, respectively. Warrants From time to time, the Company issues warrants to purchase shares of the Company’s common stock to investors, lenders, underwriters and other non-employees for services rendered or to be rendered in the future, or pursuant to settlement agreements. A summary of warrant activity for the three months ended March 31, 2021 is as follows: SCHEDULE OF WARRANTS ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares Subject to Warrants Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Avg. Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 58%">Warrants outstanding - January 1, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pii_c20210101__20210331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z0sKRNSdNGtb" style="width: 17%; text-align: right" title="Number of Shares Warrants Outstanding, beginning balance">780,386</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1_iS_pii_c20210101__20210331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zxs1sKxprXo2" style="width: 17%; text-align: right" title="Weighted Avg. Exercise Price, Outstanding, beginning balance">2.12</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pii_d0_c20210101__20210331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zYSavWRCFRf6" style="text-align: right" title="Number of Shares Warrants Outstanding, Granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pii_d0_c20210101__20210331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z6PQkXy7vCdf" style="text-align: right" title="Number of Shares Warrants Outstanding, Exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_pii_d0_c20210101__20210331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zxQz3lYErLUb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares Warrants Outstanding, Expired">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Warrants outstanding and exercisable - March 31, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber_iE_pii_c20210101__20210331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z0NsK3lY7U33" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares Warrants Outstanding and Exercisable, ending balance">780,386</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice1_iE_pii_c20210101__20210331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zu62Lb49Dibk" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Avg. Exercise Price, Outstanding and Exercisable, ending balance">2.12</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Weighted average remaining contractual life of the outstanding warrants in years - March 31, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210101__20210331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z1hQg86T2xcl" title="Weighted average remaining contractual life of the outstanding warrants in years">3.28</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Warrants outstanding and exercisable as of March 31, 2021 are as follows: SCHEDULE OF WARRANTS OUTSTANDING AND WARRANTS EXERCISABLE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Warrant Series</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Issue Date</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Warrants Outstanding</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Exercise Price</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center">Expiration Date</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 18%; text-align: left">Lender warrants</td><td style="width: 2%"> </td> <td style="width: 18%; text-align: center">5/11/2015</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pii_c20210331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsMember_z26FNFSxYW2c" style="width: 17%; text-align: right">125,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pii_c20210331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsMember_zuIoVX87Coll" style="width: 17%; text-align: right">1.79</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 18%; text-align: center">5/11/2025</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Settlement warrants</td><td> </td> <td style="text-align: center">8/16/2016</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pii_c20210331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SettlementWarrantsMember_zNS6Oj4FBji3" style="text-align: right">40,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pii_c20210331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SettlementWarrantsMember_zTOn4mJMasR7" style="text-align: right">3.75</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center">8/16/2021</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Lender warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt">7/19/2017</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pii_c20210331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsOneMember_zxoUfxuG9ZN5" style="border-bottom: Black 1.5pt solid; text-align: right">615,386</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pii_c20210331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsOneMember_zUULhW5rYRz6" style="padding-bottom: 1.5pt; text-align: right">2.08</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt">7/19/2024</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pii_c20210331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zQ4uPmqpDAA4" style="border-bottom: Black 2.5pt double; text-align: right">780,386</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pii_c20210331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zkB4MRj9LJ65" style="padding-bottom: 2.5pt; text-align: right">2.12</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"> </td></tr> </table> Subsidiary Stock-Based Transactions The Company recognized $57 in stock-based compensation expense related to subsidiary stock options during the three months ended March 31, 2021. Stock-Based Compensation Summary <p id="xdx_893_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zPf94M1fMVOe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recorded stock-based compensation related to equity instruments granted to employees, directors and consultants as follows: SCHEDULE OF STOCK BASED COMPENSATION GRANTED TO EMPLOYEES DIRECTORS CONSULTANTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; font-size: 12pt"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">For the Three Months Ended March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; font-size: 12pt"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 58%; text-align: left">Employees - selling, general and administrative</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20210101__20210331__srt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_zqLg6N7ohEqi" style="width: 17%; text-align: right">755</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20200101__20200331__srt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_zVK8EOEZz3h4" style="width: 17%; text-align: right">436</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">Directors - selling, general and administrative</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20210101__20210331__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_zdIO2vFfsvfb" style="border-bottom: Black 1.5pt solid; text-align: right">100</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20200101__20200331__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_zyYqlyaLUvQ3" style="border-bottom: Black 1.5pt solid; text-align: right">97</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20210101__20210331_zb6wWw44N5M7" style="border-bottom: Black 2.5pt double; text-align: right">855</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20200101__20200331_z5klcv9owYSc" style="border-bottom: Black 2.5pt double; text-align: right">533</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

11301

1.70

3.96

27000

200000

22500

30000

7500

57000

22755

5000000

0.001

440000

11000

2000000

4077

SCHEDULE OF STOCK OPTION PLAN ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Avg. Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Avg. Remaining Contractual Life</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Options outstanding - January 1, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_c20210101__20210331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zQBmc4kMwVhg" style="width: 11%; text-align: right" title="Number of shares, Outstanding, Beginning balance">3,030,033</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20210101__20210331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zWRQg02wE7F1" style="width: 11%; text-align: right" title="Weighted Avg. Exercise Price, Outstanding, Beginning balance">5.43</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Options granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pii_c20210101__20210331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zLztR25tfFnc" style="text-align: right" title="Number of shares, Options granted">67,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20210331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_pii" style="text-align: right" title="Weighted Avg. Exercise Price, Options granted">8.07</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Options exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pii_di_c20210101__20210331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zvDyFrjOrgYi" style="text-align: right" title="Number of shares, Options exercised">(11,301</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20210101__20210331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_pii" style="text-align: right" title="Weighted Avg. Exercise Price, Options exercised">2.42</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Options cancelled/forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pii_di_c20210101__20210331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_ztoBQ3zKa037" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, Options cancelled/forfeited">(28,195</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20210331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_pii" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Avg. Exercise Price, Options cancelled/forfeited">5.45</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Options outstanding - March 31, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pii_c20210101__20210331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zGacMeQIYEmj" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, Outstanding, Ending balance">3,057,537</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pii_c20210101__20210331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zD7XP8mJSJOa" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Avg. Exercise Price, Outstanding, Ending balance">5.50</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20210331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zfWG2FhnyP39" title="Weighted Avg. Remaining Contractual Life, Options outstanding">5.54</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20210101__20210331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_z4wlC3O4fHN2" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate Intrinsic Value, Options outstanding">5,287</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Options exercisable</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pii_c20210101__20210331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zV2gtcj2pvhk" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, Options exercisable">2,169,441</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pii_c20210101__20210331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zidNlqyLJ5Cl" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Avg. Exercise Price, Exercisable Ending Balance">4.85</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210101__20210331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_z52T4ZJfhmHa" title="Weighted Avg. Remaining Contractual Life, Options exercisable">5.04</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pn3n3_c20210101__20210331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zKr96ZcOxQMe" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate Intrinsic Value, Options exercisable">4,944</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Options vested and expected to vest</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pii_c20210101__20210331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zOjjT6S9MTk6" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, Options vested and expected to vest">2,968,979</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pii_c20210101__20210331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zUDVBi33bK69" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Avg. Exercise Price, Vested and expected to vest">5.45</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210101__20210331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zGmY9NUZ0vu4" title="Weighted Avg. Remaining Contractual Life, Options vested and expected to vest">5.50</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pn3n3_c20210101__20210331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zalPGT9Krra8" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate Intrinsic Value, Options vested and expected to vest">5,254</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

3030033

5.43

67000

8.07

11301

2.42

28195

5.45

3057537

5.50

P5Y6M14D

5287000

2169441

4.85

P5Y14D

4944000

2968979

5.45

P5Y6M

5254000

6.75

P10Y

Vesting terms for options granted to employees and consultants during the three months ended March 31, 2021 were as follows: 25% of the shares subject to the option vest and become exercisable on the first anniversary of the grant date and the remaining 75% of the shares subject to the option vest and become exercisable quarterly in equal installments thereafter over three years. Certain option awards provide for accelerated vesting if there is a change in control (as defined in the Plans) and in the event of certain modifications to the option award agreement.

The table below illustrates the fair value per share determined using the Black-Scholes-Merton option pricing model with the following assumptions used for valuing options granted to employees: SCHEDULE OF FAIR VALUE ASSUMPTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; font-size: 12pt"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Weighted-average fair value of options granted</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210101__20210331__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_pii" style="width: 20%; text-align: right" title="Weighted-average fair value of options granted">4.96</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected terms (in years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20210331__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zDdzrjuqv3Vb" title="Expected terms (in years)">6.11</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pii_dp_uPure_c20210101__20210331__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zfhgn5u3Wbeg" title="Expected volatility">69</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pii_dp_uPure_c20210101__20210331__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_z26PSaMYi3h4" title="Risk-free interest rate, minimum">0.39-<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pii_dp_uPure_c20210101__20210331__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zxFZio2b78w1" title="Risk-free interest rate, maximum">0.45 </td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pii_d0_c20210101__20210331__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zApsqMQGM392" style="text-align: right" title="Dividend yield">-</td><td style="text-align: left"> </td></tr> </table>

4.96

P6Y1M9D

0.69

0.0039

0.0045

-0

<p id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zXf7tnS5gMlg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes information about stock options outstanding and exercisable at March 31, 2021: SCHEDULE OF STOCK OPTION OUTSTANDING AND EXERCISABLE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; font-size: 12pt"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">Options Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">Options Exercisable</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Range of Exercise Prices</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom">Number Outstanding</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom">Weighted Average Remaining Contractual Life in Years</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">Number Exercisable</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%">$<span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pii_c20210101__20210331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zIzxscWCvZRa" title="Range of Exercise Prices, minimum">1.47 - $<span id="xdx_902_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pii_c20210101__20210331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zvY6pucAW21e" title="Range of Exercise Prices, maximum">2.60</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pii_c20210331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zhCobX9zUge8" style="width: 9%; text-align: right" title="Number of Options Outstanding">760,318</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20210101__20210331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_z4Eu38QKf3Ld" title="Weighted Average Remaining Contractual Life in Years">5.38</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pii_c20210331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zqzJ9YryPCpg" style="width: 9%; text-align: right" title="Weighted Average Exercise Price">2.06</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pii_c20210331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zII3zPlo9uo1" style="width: 9%; text-align: right" title="Number Exercisable">750,557</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pii_c20210331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zdFOxDV09k87" style="width: 9%; text-align: right" title="Weighted Average Exercisable Exercise Price">2.06</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>$<span id="xdx_904_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pii_c20210101__20210331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zTIsBtOudiR9" title="Range of Exercise Prices, minimum">2.76 - $<span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pii_c20210101__20210331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zqIZB7Rj6qa2" title="Range of Exercise Prices, maximum">4.66</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pii_c20210331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zclDCYjrXa26" style="text-align: right" title="Number of Options Outstanding">513,628</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20210101__20210331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_znNCURnrOuD9" title="Weighted Average Remaining Contractual Life in Years">5.51</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pii_c20210331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zcQMhnHQCkE4" style="text-align: right" title="Weighted Average Exercise Price">3.98</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pii_c20210331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zSSVkTnHKzl9" style="text-align: right" title="Number Exercisable">442,498</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pii_c20210331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zpg9p6XECJ22" style="text-align: right" title="Weighted Average Exercisable Exercise Price">3.97</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>$<span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pii_c20210101__20210331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zsJU1pf2QDC3">5.49 - $<span id="xdx_909_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pii_c20210101__20210331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zINYFiSOtQ38">6.36</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pii_c20210331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zzt4RShrpL15" style="text-align: right" title="Number of Options Outstanding">470,350</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20210101__20210331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zDKruzbpDZ4g" title="Weighted Average Remaining Contractual Life in Years">6.84</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pii_c20210331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zjmQ98zCm1Ua" style="text-align: right" title="Weighted Average Exercise Price">6.12</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pii_c20210331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zS3Om2EGL1X2" style="text-align: right" title="Number Exercisable">320,023</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pii_c20210331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zDGq3eY9VmTc" style="text-align: right" title="Weighted Average Exercisable Exercise Price">6.13</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">$<span id="xdx_900_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pii_c20210101__20210331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zj3mtY0epdB1">6.64 - $<span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pii_c20210101__20210331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zP82CbYtg4ae">8.99</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pii_c20210331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_z3BaNflDpmIe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options Outstanding">1,313,241</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20210101__20210331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zmvWRUTtpGP1" title="Weighted Average Remaining Contractual Life in Years">5.18</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_983_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pii_c20210331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zWWsM9Ycxc7j" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Exercise Price">7.86</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pii_c20210331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zl3g8K7NyBdf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number Exercisable">656,363</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pii_c20210331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zBoji5f2t4Xb" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Exercisable Exercise Price">7.99</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">$1.47 - $8.99</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pii_c20210331_z6xAd5ExihJ4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options Outstanding">3,057,537</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20210101__20210331_zQ03DcxDigca" title="Weighted Average Remaining Contractual Life in Years">5.54</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_985_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pii_c20210331_zSVEN7yVJ1Bf" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Exercise Price">5.50</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pii_c20210331_zKc4Plkz5tac" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number Exercisable">2,169,441</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pii_c20210331_zkmhxPHdNUfc" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Exercisable Exercise Price">4.85</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table>

1.47

2.60

760318

P5Y4M17D

2.06

750557

2.06

2.76

4.66

513628

P5Y6M3D

3.98

442498

3.97

5.49

6.36

470350

P6Y10M2D

6.12

320023

6.13

6.64

8.99

1313241

P5Y2M4D

7.86

656363

7.99

1.47

8.99

3057537

P5Y6M14D

5.50

2169441

4.85

2582000

P4Y7M2D

452000

263000

63000

300000

2670000

A summary of the Company’s RSU activity and related information for the three months ended March 31, 2021 is as follows: SCHEDULE OF RESTRICTED STOCK UNITS ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Number of RSUs</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Weighted Average Grant Date Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%">RSUs unvested - January 1, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pii_c20210101__20210331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zdRqi6cCCf73" style="width: 18%; text-align: right" title="Number of RSUs unvested, Outstanding, Beginning balance">1,601,509</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pii_c20210101__20210331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zSJlHR0n6hM3" style="width: 18%; text-align: right" title="Weighted Average Grant Date Fair Value, Beginning balance">3.14</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">RSUs granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pii_c20210101__20210331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zbhYZcRK36Jl" style="text-align: right" title="Number of RSUs granted">300,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_c20210101__20210331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zCfAOOQz4RC3" style="text-align: right" title="Weighted Average Grant Date Fair Value, RSUs granted">8.90</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">RSUs vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pii_di_c20210101__20210331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z0NDBr6Y9dR6" style="text-align: right" title="Number of RSUs vested">(252,755</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pii_c20210101__20210331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zWcNj3UPryL1" style="text-align: right" title="Weighted Average Grant Date Fair Value, RSUs vested">2.38</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">RSUs cancelled/forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_pii_d0_c20210101__20210331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z7lgV5z5bav9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of RSUs cancelled/forfeited">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pii_c20210101__20210331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zMeI0xvJzd8l" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Grant Date Fair Value, RSUs cancelled/forfeited">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">RSUs unvested at March 31, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pii_c20210101__20210331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zNgiUq1azNH1" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of RSUs unvested, Outstanding, Ending balance">1,648,754</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pii_c20210101__20210331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zHF6fyUBF9O1" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Grant Date Fair Value, Ending balance">4.30</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

1601509

3.14

300000

8.90

252755

2.38

-0

1648754

4.30

3687000

P0Y9M25D

346000

259000

A summary of warrant activity for the three months ended March 31, 2021 is as follows: SCHEDULE OF WARRANTS ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares Subject to Warrants Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Avg. Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 58%">Warrants outstanding - January 1, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pii_c20210101__20210331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z0sKRNSdNGtb" style="width: 17%; text-align: right" title="Number of Shares Warrants Outstanding, beginning balance">780,386</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1_iS_pii_c20210101__20210331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zxs1sKxprXo2" style="width: 17%; text-align: right" title="Weighted Avg. Exercise Price, Outstanding, beginning balance">2.12</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pii_d0_c20210101__20210331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zYSavWRCFRf6" style="text-align: right" title="Number of Shares Warrants Outstanding, Granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pii_d0_c20210101__20210331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z6PQkXy7vCdf" style="text-align: right" title="Number of Shares Warrants Outstanding, Exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_pii_d0_c20210101__20210331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zxQz3lYErLUb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares Warrants Outstanding, Expired">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Warrants outstanding and exercisable - March 31, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber_iE_pii_c20210101__20210331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z0NsK3lY7U33" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares Warrants Outstanding and Exercisable, ending balance">780,386</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice1_iE_pii_c20210101__20210331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zu62Lb49Dibk" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Avg. Exercise Price, Outstanding and Exercisable, ending balance">2.12</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Weighted average remaining contractual life of the outstanding warrants in years - March 31, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210101__20210331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z1hQg86T2xcl" title="Weighted average remaining contractual life of the outstanding warrants in years">3.28</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

780386

2.12

-0

780386 2.12 P3Y3M10D Warrants outstanding and exercisable as of March 31, 2021 are as follows: SCHEDULE OF WARRANTS OUTSTANDING AND WARRANTS EXERCISABLE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Warrant Series</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Issue Date</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Warrants Outstanding</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Exercise Price</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center">Expiration Date</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 18%; text-align: left">Lender warrants</td><td style="width: 2%"> </td> <td style="width: 18%; text-align: center">5/11/2015</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pii_c20210331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsMember_z26FNFSxYW2c" style="width: 17%; text-align: right">125,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pii_c20210331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsMember_zuIoVX87Coll" style="width: 17%; text-align: right">1.79</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 18%; text-align: center">5/11/2025</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Settlement warrants</td><td> </td> <td style="text-align: center">8/16/2016</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pii_c20210331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SettlementWarrantsMember_zNS6Oj4FBji3" style="text-align: right">40,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pii_c20210331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SettlementWarrantsMember_zTOn4mJMasR7" style="text-align: right">3.75</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center">8/16/2021</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Lender warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt">7/19/2017</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pii_c20210331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsOneMember_zxoUfxuG9ZN5" style="border-bottom: Black 1.5pt solid; text-align: right">615,386</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pii_c20210331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsOneMember_zUULhW5rYRz6" style="padding-bottom: 1.5pt; text-align: right">2.08</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt">7/19/2024</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pii_c20210331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zQ4uPmqpDAA4" style="border-bottom: Black 2.5pt double; text-align: right">780,386</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pii_c20210331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zkB4MRj9LJ65" style="padding-bottom: 2.5pt; text-align: right">2.12</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"> </td></tr> </table> 2015-05-11

125000

1.79

2025-05-11 2016-08-16

40000

3.75

2021-08-16 2017-07-19

615386

2.08

2024-07-19

780386

2.12

<p id="xdx_893_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zPf94M1fMVOe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recorded stock-based compensation related to equity instruments granted to employees, directors and consultants as follows: SCHEDULE OF STOCK BASED COMPENSATION GRANTED TO EMPLOYEES DIRECTORS CONSULTANTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; font-size: 12pt"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">For the Three Months Ended March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; font-size: 12pt"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 58%; text-align: left">Employees - selling, general and administrative</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20210101__20210331__srt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_zqLg6N7ohEqi" style="width: 17%; text-align: right">755</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20200101__20200331__srt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_zVK8EOEZz3h4" style="width: 17%; text-align: right">436</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">Directors - selling, general and administrative</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20210101__20210331__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_zdIO2vFfsvfb" style="border-bottom: Black 1.5pt solid; text-align: right">100</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20200101__20200331__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_zyYqlyaLUvQ3" style="border-bottom: Black 1.5pt solid; text-align: right">97</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20210101__20210331_zb6wWw44N5M7" style="border-bottom: Black 2.5pt double; text-align: right">855</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20200101__20200331_z5klcv9owYSc" style="border-bottom: Black 2.5pt double; text-align: right">533</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

755000

436000

100000

97000

855000

533000

NOTE 15. COMMITMENTS AND CONTINGENCIES Legal Novel Drug Solutions et al. In April 2018, Novel Drug Solutions, LLC and Eyecare Northwest, PA (collectively “NDS”) filed a lawsuit against the Company in the U.S. District Court of Delaware asserting claims for breach of contract. The claims stem from an asset purchase agreement between the Company and NDS entered into in 2013. In July 2019, NDS filed a second amended complaint which added a claim related to its purported termination of the APA. In October 2019, NDS voluntarily dismissed all claims related to breach of contract, leaving only claims related to the scope of the post-termination obligations to be litigated. On October 29, 2020, at a hearing on the various dispositive motions before it, the Court found that there were triable issues of fact and reopened discovery for limited purposes. NDS is seeking unspecified damages, interest, attorney’s fees and other costs. The Company believes the claims are meritless and has previously and will continue to dispute all claims asserted against it and intends to vigorously defend against these allegations. Nonetheless, the Company cannot predict the eventual outcome of this litigation and it could result in substantial costs, losses and a diversion of management’s resources and attention, which could harm the Company’s business and the value of its common stock. Product and Professional Liability Product and professional liability litigation represents an inherent risk to all firms in the pharmaceutical and pharmacy industry. We utilize traditional third-party insurance policies with regard to our product and professional liability claims. Such insurance coverage at any given time reflects current market conditions, including cost and availability, when the policy is written. John Erick et al. In January 2018, John Erick and Deborah Ferrell, successors-in-interest and heirs of Jade Erick, (collectively “Erick”) filed a lawsuit in the San Diego County Superior against Kim Kelly, ND, MPH asserting claims related to the death of Jade Erick. In April 2018, Erick filed an amendment to the lawsuit, naming us as a co-defendant. In September 2018, co-defendant Dr. Kelly filed a cross-complaint against the Company and various entities affiliated with Spectrum Laboratory Products, Inc., Spectrum Chemical Manufacturing Corp. and Spectrum Pharmacy Products, Inc. (collectively “Spectrum”). The cross-complaint seeks indemnity and contribution from the Company and Spectrum. The Company answered the claims filed by Dr. Kelly in October 2018. The case is currently in the discovery phase. Erick is seeking unspecified damages, interest, attorney’s fees and other costs. The Company believes the claims are meritless and has previously and will continue to dispute all claims asserted against it and intends to vigorously defend against these allegations. Nonetheless, the Company cannot predict the eventual outcome of this litigation, it could result in substantial costs, losses and a diversion of management’s resources and attention, which could harm the Company’s business and the value of its common stock. General and Other In the ordinary course of business, the Company may face various claims brought by third parties and it may, from time to time, make claims or take legal actions to assert its rights, including intellectual property disputes, contractual disputes and other commercial disputes. Any of these claims could subject the Company to litigation. Indemnities In addition to the indemnification provisions contained in the Company’s governing documents, the Company generally enters into separate indemnification agreements with each of the Company’s directors and officers. These agreements require the Company, among other things, to indemnify the director or officer against specified expenses and liabilities, such as attorneys’ fees, judgments, fines and settlements, paid by the individual in connection with any action, suit or proceeding arising out of the individual’s status or service as the Company’s director or officer, other than liabilities arising from willful misconduct or conduct that is knowingly fraudulent or deliberately dishonest, and to advance expenses incurred by the individual in connection with any proceeding against the individual with respect to which the individual may be entitled to indemnification by the Company. The Company also indemnifies its lessors in connection with its facility leases for certain claims arising from the use of the facilities. These indemnities do not provide for any limitation of the maximum potential future payments the Company could be obligated to make. Historically, the Company has not incurred any payments for these obligations and, therefore, no liabilities have been recorded for these indemnities in the accompanying condensed consolidated balance sheets. Klarity License Agreement – Related Party The Company entered into a license agreement in April 2017 and as amended in April 2018, (the “Klarity License Agreement”) with Richard L. Lindstrom, M.D., a member of its Board of Directors. Pursuant to the terms of the Klarity License Agreement, the Company licensed certain intellectual property and related rights from Dr. Lindstrom to develop, formulate, make, sell, and sub-license the topical ophthalmic solution Klarity designed to protect and rehabilitate the ocular surface (the “Klarity Product”). <span id="xdx_908_ecustom--RoyaltyPaymentDescription_c20170401__20170430__us-gaap--TypeOfArrangementAxis__custom--KlarityLicenseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_zxgNa3EFO4xk" title="Royalty payment description">Under the terms of the Klarity License Agreement, the Company is required to make royalty payments to Dr. Lindstrom ranging from 3% - 6% of net sales, dependent upon the final formulation of the Klarity Product sold. In addition, the Company is required to make certain milestone payments to Dr. Lindstrom including: (i) an initial payment of $<span id="xdx_900_eus-gaap--RoyaltyExpense_pn3n3_c20170401__20170430__srt--StatementScenarioAxis__custom--InitialPaymentMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_zHpBB8E2hj5j" title="Royalty payments">50 upon execution of the Klarity License Agreement, (ii) a second payment of $<span id="xdx_90F_eus-gaap--RoyaltyExpense_pn3n3_c20170401__20170430__srt--StatementScenarioAxis__custom--SecondPaymentMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_zGAr4sUwvMV9" title="Royalty payments">50 following the first $<span id="xdx_901_eus-gaap--RoyaltyExpense_pn3n3_c20170401__20170430__srt--StatementScenarioAxis__custom--FinalPaymentMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_zg9kzbZXYbp3" title="Royalty payments">50 in net sales of the Klarity Product; and (iii) a final payment of $<span id="xdx_90C_ecustom--NetSalesRevenue_pn3n3_c20170401__20170430__srt--StatementScenarioAxis__custom--SecondPaymentMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_ztxzVzphVAs1" title="Sales revenue net">50 following the first $<span id="xdx_901_ecustom--NetSalesRevenue_pn3n3_c20170401__20170430__srt--StatementScenarioAxis__custom--FinalPaymentMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_z7lhzj0dTf59" title="Sales revenue net">100 in net sales of the Klarity Product. All of the above referenced milestone payments are payable at the Company’s election in cash or shares of the Company’s restricted common stock. Payments totaling $35 and $55 were made during the three months ended March 31, 2021 and 2020, respectively. $<span id="xdx_90A_eus-gaap--RoyaltyExpense_pn3n3_c20210101__20210331__us-gaap--TypeOfArrangementAxis__custom--KlarityLicenseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_zg1FIJcjPs83" title="Royalty payments">35 and $<span id="xdx_90E_eus-gaap--RoyaltyExpense_pn3n3_c20200101__20200331__us-gaap--TypeOfArrangementAxis__custom--KlarityLicenseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_z15hM7XTJx" title="Royalty payments">29 was incurred as royalty expense during the three months ended March 31, 2021 and 2020, respectively, and included in accounts payable to Dr. Lindstrom. Injectable Asset Purchase Agreement – Related Party In December 2019, the Company entered into an asset purchase agreement (the “Lindstrom APA”) with Dr. Lindstrom, a member of its Board of Directors. Pursuant to the terms of the Lindstrom APA, the Company acquired certain intellectual property and related rights from Dr. Lindstrom to develop, formulate, make, sell, and sub-license an ophthalmic injectable product (the “Lindstrom Product”). Under the terms of the Lindstrom APA, <span id="xdx_906_ecustom--RoyaltyPaymentDescription_c20191201__20191231__us-gaap--TypeOfArrangementAxis__custom--InjectableAssetPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember">the Company is required to make royalty payments to Dr. Lindstrom ranging from 2% to 3% of net sales, dependent upon the final formulation and patent protection of the Lindstrom Product sold. In addition, the Company is required to make certain milestone payments to Dr. Lindstrom including an initial payment of $<span id="xdx_907_eus-gaap--RoyaltyExpense_pn3n3_c20191201__20191231__srt--StatementScenarioAxis__custom--InitialPaymentMember__us-gaap--TypeOfArrangementAxis__custom--InjectableAssetPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_zBMCqVY8Mw4e">33 upon execution of the Lindstrom APA. Dr. Lindstrom was paid $<span id="xdx_905_ecustom--MilestonePaymentInCash_pn3n3_c20210101__20210331__us-gaap--TypeOfArrangementAxis__custom--InjectableAssetPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_z3NckjCjlZe5">7 and $<span id="xdx_902_ecustom--MilestonePaymentInCash_pn3n3_c20200101__20200331__us-gaap--TypeOfArrangementAxis__custom--InjectableAssetPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_zsfF7HJ5Das4">7 in cash during the three months ended March 31, 2021 and 2020, respectively. The Company incurred $<span id="xdx_902_eus-gaap--RoyaltyExpense_pn3n3_c20210101__20210331__us-gaap--TypeOfArrangementAxis__custom--InjectableAssetPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_zKsVI2kUCBif">7 and $<span id="xdx_909_eus-gaap--RoyaltyExpense_pn3n3_c20200101__20200331__us-gaap--TypeOfArrangementAxis__custom--InjectableAssetPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_zYnehNWnouTk">38 for royalty expenses related to the Lindstrom APA during the three months ended March 31, 2021 and 2020. Eyepoint Commercial Alliance Agreement In August 2020, the Company, through its wholly owned subsidiary ImprimisRx, LLC, entered into a Commercial Alliance Agreement (the “Dexycu Agreement”) with Eyepoint Pharmaceuticals, Inc. (“Eyepoint”), pursuant to which Eyepoint granted the Company the non-exclusive right to co-promote DEXYCU® (dexamethasone intraocular suspension) 9% for the treatment of post-operative inflammation following ocular surgery in the United States. Pursuant to the Dexycu Agreement, Eyepoint will pay the Company a fee calculated based on the quarterly sales of DEXYCU in excess of predefined volumes to specific customers of the Company in the U.S. Under the terms of the Dexycu Agreement, the Company shall use commercially reasonable efforts to promote and market DEXYCU in the U.S. Subject to early termination, the Dexycu Agreement expires on August 1, 2025, subject to specified notice periods and specified limitations, either party may terminate the Dexycu Agreement in the event of (i) uncured material breach by the other party or (ii) if DEXYCU ceases to have “pass-through” payment status. In addition, subject to certain limitations, the Company may terminate the Dexycu Agreement (i) for convenience subject to an extended specified notice period or (ii) in the event Eyepoint undergoes a change of control. Eyepoint may terminate the Dexycu Agreement, subject to specified notice periods and specified limitations, if the Company fails to achieve certain minimum sales levels during specified periods. During the three months ended March 31, 2021, the Company recorded $485 in commission revenues related to the Dexycu Agreement. Sales and Marketing Agreements The Company has entered various sales and marketing agreements with certain organizations, to provide exclusive and non-exclusive sales and marketing representation services to Harrow in select geographies in the U.S., in connection with the Company’s ophthalmic pharmaceutical compounded formulations or related products. Under the terms of the sales and marketing agreements, the Company is, generally, required to make commission payments equal to <span id="xdx_908_ecustom--CommissionPaymentsPercentage_pii_dp_uPure_c20170101__20191231__us-gaap--TypeOfArrangementAxis__custom--SalesAndMarketingAgreementsMember__srt--RangeAxis__srt--MinimumMember_zPKWfQQZKAwf" title="Commission payments percentage">10% - <span id="xdx_902_ecustom--CommissionPaymentsPercentage_pii_dp_uPure_c20170101__20191231__us-gaap--TypeOfArrangementAxis__custom--SalesAndMarketingAgreementsMember__srt--RangeAxis__srt--MaximumMember_zznhjbRQkN17">14% of net sales for products above and beyond the initial existing sales amounts. In addition, the Company is required to make periodic milestone payments to certain organizations in shares of the Company’s restricted common stock if net sales in the assigned territory reach certain future levels by the end of their terms, as applicable. $0 and $83 of stock-based payments were recorded and $804 and $603 were incurred under these agreements for commission expenses during the three months ended March 31, 2021 and 2020, respectively. Asset Purchase, License and Related Agreements The Company has acquired and sourced intellectual property rights related to certain proprietary innovations from certain inventors and related parties (the “Inventors”) through multiple asset purchase agreements, license agreements, strategic agreements and commission agreements. In general, these agreements provide that the Inventors will cooperate with the Company in obtaining patent protection for the acquired intellectual property and that the Company will use commercially reasonable efforts to research, develop and commercialize a product based on the acquired intellectual property. In addition, the Company has acquired a right of first refusal on additional intellectual property and drug development opportunities presented by these Inventors. In consideration for the acquisition of the intellectual property rights, the Company is obligated to make payments to the Inventors based on the completion of certain milestones, generally consisting of: (1) a payment payable within 30 days after the issuance of the first patent in the United States arising from the acquired intellectual property (if any); (2) a payment payable within 30 days after the Company files the first investigational new drug application (“IND”) with the U.S. Food and Drug Administration (“FDA”) for the first product arising from the acquired intellectual property (if any); (3) for certain of the Inventors, a payment payable within 30 days after the Company files the first new drug application with the FDA for the first product arising from the acquired intellectual property (if any); and (4) certain royalty payments based on the net receipts received by the Company in connection with the sale or licensing of any product based on the acquired intellectual property (if any), after deducting (among other things) the Company’s development costs associated with such product. If, following five years after the date of the applicable asset purchase agreement, the Company either (a) for certain of the Inventors, has not filed an IND or, for the remaining Inventors, has not initiated a study where data is derived, or (b) has failed to generate royalty payments to the Inventors for any product based on the acquired intellectual property, the Inventors may terminate the applicable asset purchase agreement and request that the Company re-assign the acquired technology to the Inventors. $232 and $144 were incurred under these agreements as royalty expenses and included in accounts payable at March 31, 2021 and 2020, respectively.

Under the terms of the Klarity License Agreement, the Company is required to make royalty payments to Dr. Lindstrom ranging from 3% - 6% of net sales, dependent upon the final formulation of the Klarity Product sold.

50000

50000 100000 35000 55000

35000

29000

the Company is required to make royalty payments to Dr. Lindstrom ranging from 2% to 3% of net sales, dependent upon the final formulation and patent protection of the Lindstrom Product sold.

33000

7000 7000

7000

38000

485000

0.10 0.14

83000

804000

603000

In consideration for the acquisition of the intellectual property rights, the Company is obligated to make payments to the Inventors based on the completion of certain milestones, generally consisting of: (1) a payment payable within 30 days after the issuance of the first patent in the United States arising from the acquired intellectual property (if any); (2) a payment payable within 30 days after the Company files the first investigational new drug application (“IND”) with the U.S. Food and Drug Administration (“FDA”) for the first product arising from the acquired intellectual property (if any); (3) for certain of the Inventors, a payment payable within 30 days after the Company files the first new drug application with the FDA for the first product arising from the acquired intellectual property (if any); and (4) certain royalty payments based on the net receipts received by the Company in connection with the sale or licensing of any product based on the acquired intellectual property (if any), after deducting (among other things) the Company’s development costs associated with such product. If, following five years after the date of the applicable asset purchase agreement, the Company either (a) for certain of the Inventors, has not filed an IND or, for the remaining Inventors, has not initiated a study where data is derived, or (b) has failed to generate royalty payments to the Inventors for any product based on the acquired intellectual property, the Inventors may terminate the applicable asset purchase agreement and request that the Company re-assign the acquired technology to the Inventors.

232000

144000

NOTE 16. SEGMENT INFORMATION AND CONCENTRATIONS Management evaluates performance of the Company based on operating segments. Segment performance for its two operating segments is based on segment contribution. The Company’s reportable segments consist of (i) its commercial stage pharmaceutical business known as ImprimisRx; and (ii) its start-up operations associated with pharmaceutical drug development business (Pharmaceutical Drug Development). Segment contribution for the segments represents net revenues less cost of sales, research and development, selling and marketing expenses, and select general and administrative expenses. The Company does not evaluate the following items at the segment level: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Selling, general and administrative expenses that result from shared infrastructure, including certain expenses associated with legal matters, public company costs (e.g. investor relations), board of directors and principal executive officers and other like shared expenses.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Operating expenses within selling, general and administrative expenses that result from the impact of corporate initiatives. Corporate initiatives primarily include integration, restructuring, acquisition and other shared costs.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Other select revenues and operating expenses including R&D expenses, amortization, and asset sales and impairments, net as not all such information has been accounted for at the segment level, or such information has not been used by all segments.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif">Total assets including capital expenditures.</td></tr> </table> The Company defines segment net revenues as pharmaceutical compounded drug sales, licenses, commissions and other revenue derived from related agreements. Cost of sales within segment contribution includes direct and indirect costs to manufacture formulations and sell products, including active pharmaceutical ingredients, personnel costs, packaging, storage, royalties, shipping and handling costs, manufacturing equipment and tenant improvements depreciation, the write-off of obsolete inventory and other related expenses. Selling, general and administrative expenses consist mainly of personnel-related costs, marketing and promotion costs, distribution costs, professional service costs, insurance, depreciation, facilities costs, transaction costs, and professional services costs which are general in nature and attributable to the segment. Segment net revenues, segment operating expenses and segment contribution information consisted of the following for the three months ended March 31, 2021: SCHEDULE OF SEGMENT NET REVENUES, SEGMENT OPERATING EXPENSES AND SEGMENT CONTRIBUTION <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; font-size: 12pt"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">For the Three Months Ended March 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; font-size: 12pt"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">ImprimisRx</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">Pharmaceutical Drug Development</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 12pt"> </td><td style="font-size: 12pt"> </td> <td colspan="2" style="font-size: 12pt"> </td><td style="font-size: 12pt"> </td><td style="font-size: 12pt"> </td> <td colspan="2" style="font-size: 12pt"> </td><td style="font-size: 12pt"> </td><td style="font-size: 12pt"> </td> <td colspan="2" style="font-size: 12pt"> </td><td style="font-size: 12pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 49%; text-align: left">Net revenues</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210101__20210331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember_pn3n3" style="width: 13%; text-align: right" title="Net Revenues">15,443</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210101__20210331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="width: 13%; text-align: right" title="Net Revenues">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210101__20210331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="width: 13%; text-align: right" title="Net Revenues">15,443</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Cost of sales</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_c20210101__20210331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember_zgRmtQUiXajl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales">(3,770</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--CostOfGoodsAndServicesSold_c20210101__20210331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_c20210101__20210331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_znNEJUiBCnsf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales">(3,770</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Gross profit</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--GrossProfit_c20210101__20210331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember_pn3n3" style="text-align: right" title="Gross profit">11,673</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--GrossProfit_c20210101__20210331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="text-align: right" title="Gross profit">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--GrossProfit_c20210101__20210331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="text-align: right" title="Gross profit">11,673</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 12pt"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating expenses:</td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Selling, general and administrative</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--SellingGeneralAndAdministrativeExpense_c20210101__20210331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember_pn3n3" style="text-align: right" title="Selling, general and administrative">5,771</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--SellingGeneralAndAdministrativeExpense_c20210101__20210331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="text-align: right" title="Selling, general and administrative">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--SellingGeneralAndAdministrativeExpense_c20210101__20210331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="text-align: right" title="Selling, general and administrative">5,771</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1.5pt; text-align: left">Research and development</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ResearchAndDevelopmentExpense_c20210101__20210331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">210</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ResearchAndDevelopmentExpense_c20210101__20210331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">13</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--ResearchAndDevelopmentExpense_c20210101__20210331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">223</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">Segment contribution</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_ecustom--SegmentContribution_c20210101__20210331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">5,692</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_982_ecustom--SegmentContribution_c20210101__20210331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">(13</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_ecustom--SegmentContribution_c20210101__20210331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">5,679</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Corporate</td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--OperatingIncomeLoss_c20210101__20210331__srt--ConsolidationItemsAxis__us-gaap--CorporateNonSegmentMember_pn3n3" style="text-align: right" title="Operating income (loss)">2,353</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Research and development</td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--OperatingIncomeLoss_c20210101__20210331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pn3n3" style="text-align: right" title="Operating income (loss)">369</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Amortization</td><td style="padding-bottom: 1.5pt; font-size: 12pt"> </td> <td style="padding-bottom: 1.5pt; font-size: 12pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; font-size: 12pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; font-size: 12pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; font-size: 12pt"> </td> <td style="padding-bottom: 1.5pt; font-size: 12pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; font-size: 12pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; font-size: 12pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--AdjustmentForAmortization_c20210101__20210331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization">40</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 2.5pt; text-align: left">Operating income</td><td style="padding-bottom: 2.5pt; font-size: 12pt"> </td> <td style="padding-bottom: 2.5pt; font-size: 12pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; font-size: 12pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; font-size: 12pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; font-size: 12pt"> </td> <td style="padding-bottom: 2.5pt; font-size: 12pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; font-size: 12pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; font-size: 12pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--OperatingIncomeLoss_c20210101__20210331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating income (loss)">2,917</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; font-size: 12pt"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">For the Three Months Ended March 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; font-size: 12pt"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">ImprimisRx</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">Pharmaceutical Drug Development</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 49%; text-align: left">Net revenues</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20200331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember_pn3n3" style="width: 13%; text-align: right" title="Net Revenues">11,817</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20200331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="width: 13%; text-align: right" title="Net Revenues">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20200331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="width: 13%; text-align: right" title="Net Revenues">11,817</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Cost of sales</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_c20200101__20200331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember_zkd6bxNjjFS" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales">(3,626</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--CostOfGoodsAndServicesSold_c20200101__20200331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_c20200101__20200331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zQVIUJKO0M5c" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales">(3,626</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Gross profit</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--GrossProfit_c20200101__20200331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember_pn3n3" style="text-align: right" title="Gross profit">8,191</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--GrossProfit_c20200101__20200331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="text-align: right" title="Gross profit">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--GrossProfit_c20200101__20200331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="text-align: right" title="Gross profit">8,191</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 12pt"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating expenses:</td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Selling, general and administrative</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--SellingGeneralAndAdministrativeExpense_c20200101__20200331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember_pn3n3" style="text-align: right" title="Selling, general and administrative">6,640</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--SellingGeneralAndAdministrativeExpense_c20200101__20200331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="text-align: right" title="Selling, general and administrative">44</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--SellingGeneralAndAdministrativeExpense_c20200101__20200331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="text-align: right" title="Selling, general and administrative">6,684</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1.5pt; text-align: left">Research and development</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--ResearchAndDevelopmentExpense_c20200101__20200331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">43</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--ResearchAndDevelopmentExpense_c20200101__20200331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">11</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--ResearchAndDevelopmentExpense_c20200101__20200331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">54</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">Segment contribution</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_ecustom--SegmentContribution_c20200101__20200331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">1,508</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_ecustom--SegmentContribution_c20200101__20200331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">(55</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_ecustom--SegmentContribution_c20200101__20200331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">1,453</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Corporate</td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--OperatingIncomeLoss_pn3n3_c20200101__20200331__srt--ConsolidationItemsAxis__us-gaap--CorporateNonSegmentMember_zVn8eRZpOm57" style="text-align: right" title="Operating income (loss)">1,687</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Research and development</td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--OperatingIncomeLoss_pn3n3_c20200101__20200331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zACmAwnplGe6" style="text-align: right" title="Operating income (loss)">349</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Amortization</td><td style="padding-bottom: 1.5pt; font-size: 12pt"> </td> <td style="padding-bottom: 1.5pt; font-size: 12pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; font-size: 12pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; font-size: 12pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; font-size: 12pt"> </td> <td style="padding-bottom: 1.5pt; font-size: 12pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; font-size: 12pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; font-size: 12pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--AdjustmentForAmortization_c20200101__20200331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization">45</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 2.5pt; text-align: left">Operating loss</td><td style="padding-bottom: 2.5pt; font-size: 12pt"> </td> <td style="padding-bottom: 2.5pt; font-size: 12pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; font-size: 12pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; font-size: 12pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; font-size: 12pt"> </td> <td style="padding-bottom: 2.5pt; font-size: 12pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; font-size: 12pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; font-size: 12pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--OperatingIncomeLoss_c20200101__20200331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating income (loss)">(628</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> The Company categorizes revenues by geographic area based on selling location. All operations are currently located in the U.S.; therefore, total revenues are attributed to the U.S. All long-lived assets at March 31, 2021 and December 31, 2020 were located in the U.S. Concentrations The Company sells its compounded formulations to a large number of customers. There were no customers who comprised more than 10% of the Company’s total pharmacy sales for the three months ended March 31, 2021 and 2020. The Company receives its active pharmaceutical ingredients from three main suppliers. These suppliers collectively accounted for <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pii_dp_uPure_c20210101__20210331__us-gaap--ConcentrationRiskByTypeAxis__custom--ThreeMainSuppliersMember_z5lPpj0xdVXc" title="Percentage of sales derived from large number of customer">82% and <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pii_dp_uPure_c20200101__20200331__us-gaap--ConcentrationRiskByTypeAxis__custom--ThreeMainSuppliersMember_z1uN7Z7QNOnf" title="Percentage of sales derived from large number of customer">78% of active pharmaceutical ingredient purchases during the three months ended March 31, 2021 and 2020, respectively.

two

Segment net revenues, segment operating expenses and segment contribution information consisted of the following for the three months ended March 31, 2021: SCHEDULE OF SEGMENT NET REVENUES, SEGMENT OPERATING EXPENSES AND SEGMENT CONTRIBUTION <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; font-size: 12pt"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">For the Three Months Ended March 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; font-size: 12pt"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">ImprimisRx</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">Pharmaceutical Drug Development</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 12pt"> </td><td style="font-size: 12pt"> </td> <td colspan="2" style="font-size: 12pt"> </td><td style="font-size: 12pt"> </td><td style="font-size: 12pt"> </td> <td colspan="2" style="font-size: 12pt"> </td><td style="font-size: 12pt"> </td><td style="font-size: 12pt"> </td> <td colspan="2" style="font-size: 12pt"> </td><td style="font-size: 12pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 49%; text-align: left">Net revenues</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210101__20210331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember_pn3n3" style="width: 13%; text-align: right" title="Net Revenues">15,443</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210101__20210331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="width: 13%; text-align: right" title="Net Revenues">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210101__20210331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="width: 13%; text-align: right" title="Net Revenues">15,443</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Cost of sales</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_c20210101__20210331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember_zgRmtQUiXajl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales">(3,770</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--CostOfGoodsAndServicesSold_c20210101__20210331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_c20210101__20210331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_znNEJUiBCnsf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales">(3,770</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Gross profit</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--GrossProfit_c20210101__20210331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember_pn3n3" style="text-align: right" title="Gross profit">11,673</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--GrossProfit_c20210101__20210331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="text-align: right" title="Gross profit">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--GrossProfit_c20210101__20210331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="text-align: right" title="Gross profit">11,673</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 12pt"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating expenses:</td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Selling, general and administrative</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--SellingGeneralAndAdministrativeExpense_c20210101__20210331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember_pn3n3" style="text-align: right" title="Selling, general and administrative">5,771</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--SellingGeneralAndAdministrativeExpense_c20210101__20210331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="text-align: right" title="Selling, general and administrative">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--SellingGeneralAndAdministrativeExpense_c20210101__20210331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="text-align: right" title="Selling, general and administrative">5,771</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1.5pt; text-align: left">Research and development</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ResearchAndDevelopmentExpense_c20210101__20210331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">210</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ResearchAndDevelopmentExpense_c20210101__20210331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">13</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--ResearchAndDevelopmentExpense_c20210101__20210331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">223</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">Segment contribution</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_ecustom--SegmentContribution_c20210101__20210331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">5,692</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_982_ecustom--SegmentContribution_c20210101__20210331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">(13</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_ecustom--SegmentContribution_c20210101__20210331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">5,679</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Corporate</td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--OperatingIncomeLoss_c20210101__20210331__srt--ConsolidationItemsAxis__us-gaap--CorporateNonSegmentMember_pn3n3" style="text-align: right" title="Operating income (loss)">2,353</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Research and development</td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--OperatingIncomeLoss_c20210101__20210331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pn3n3" style="text-align: right" title="Operating income (loss)">369</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Amortization</td><td style="padding-bottom: 1.5pt; font-size: 12pt"> </td> <td style="padding-bottom: 1.5pt; font-size: 12pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; font-size: 12pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; font-size: 12pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; font-size: 12pt"> </td> <td style="padding-bottom: 1.5pt; font-size: 12pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; font-size: 12pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; font-size: 12pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--AdjustmentForAmortization_c20210101__20210331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization">40</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 2.5pt; text-align: left">Operating income</td><td style="padding-bottom: 2.5pt; font-size: 12pt"> </td> <td style="padding-bottom: 2.5pt; font-size: 12pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; font-size: 12pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; font-size: 12pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; font-size: 12pt"> </td> <td style="padding-bottom: 2.5pt; font-size: 12pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; font-size: 12pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; font-size: 12pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--OperatingIncomeLoss_c20210101__20210331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating income (loss)">2,917</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; font-size: 12pt"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">For the Three Months Ended March 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; font-size: 12pt"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">ImprimisRx</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">Pharmaceutical Drug Development</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 49%; text-align: left">Net revenues</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20200331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember_pn3n3" style="width: 13%; text-align: right" title="Net Revenues">11,817</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20200331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="width: 13%; text-align: right" title="Net Revenues">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20200331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="width: 13%; text-align: right" title="Net Revenues">11,817</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Cost of sales</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_c20200101__20200331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember_zkd6bxNjjFS" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales">(3,626</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--CostOfGoodsAndServicesSold_c20200101__20200331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_c20200101__20200331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zQVIUJKO0M5c" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales">(3,626</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Gross profit</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--GrossProfit_c20200101__20200331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember_pn3n3" style="text-align: right" title="Gross profit">8,191</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--GrossProfit_c20200101__20200331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="text-align: right" title="Gross profit">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--GrossProfit_c20200101__20200331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="text-align: right" title="Gross profit">8,191</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 12pt"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating expenses:</td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Selling, general and administrative</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--SellingGeneralAndAdministrativeExpense_c20200101__20200331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember_pn3n3" style="text-align: right" title="Selling, general and administrative">6,640</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--SellingGeneralAndAdministrativeExpense_c20200101__20200331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="text-align: right" title="Selling, general and administrative">44</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--SellingGeneralAndAdministrativeExpense_c20200101__20200331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="text-align: right" title="Selling, general and administrative">6,684</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1.5pt; text-align: left">Research and development</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--ResearchAndDevelopmentExpense_c20200101__20200331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">43</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--ResearchAndDevelopmentExpense_c20200101__20200331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">11</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--ResearchAndDevelopmentExpense_c20200101__20200331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">54</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">Segment contribution</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_ecustom--SegmentContribution_c20200101__20200331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">1,508</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_ecustom--SegmentContribution_c20200101__20200331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">(55</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_ecustom--SegmentContribution_c20200101__20200331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">1,453</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Corporate</td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--OperatingIncomeLoss_pn3n3_c20200101__20200331__srt--ConsolidationItemsAxis__us-gaap--CorporateNonSegmentMember_zVn8eRZpOm57" style="text-align: right" title="Operating income (loss)">1,687</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Research and development</td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--OperatingIncomeLoss_pn3n3_c20200101__20200331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zACmAwnplGe6" style="text-align: right" title="Operating income (loss)">349</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Amortization</td><td style="padding-bottom: 1.5pt; font-size: 12pt"> </td> <td style="padding-bottom: 1.5pt; font-size: 12pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; font-size: 12pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; font-size: 12pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; font-size: 12pt"> </td> <td style="padding-bottom: 1.5pt; font-size: 12pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; font-size: 12pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; font-size: 12pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--AdjustmentForAmortization_c20200101__20200331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization">45</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 2.5pt; text-align: left">Operating loss</td><td style="padding-bottom: 2.5pt; font-size: 12pt"> </td> <td style="padding-bottom: 2.5pt; font-size: 12pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; font-size: 12pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; font-size: 12pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; font-size: 12pt"> </td> <td style="padding-bottom: 2.5pt; font-size: 12pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; font-size: 12pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; font-size: 12pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--OperatingIncomeLoss_c20200101__20200331__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating income (loss)">(628</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table>

15443000

3770000

11673000

5771000

210000

13000

223000

5692000 -13000 5679000

2353000

369000

40000

2917000

11817000

3626000

8191000

6640000

44000

6684000

43000

11000

54000

1508000 -55000 1453000

1687000

349000

45000

-628000

0.10

0.82

0.78

NOTE 17. SUBSEQUENT EVENTS The Company has performed an evaluation of events occurring subsequent to March 31, 2021 through the filing date of this Quarterly Report. Based on its evaluation, no events other than those described below need to be disclosed. Vesting and Exercise of Equity Awards In April 2021, the Company issued <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pii_c20210401__20210430__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--MarkLBaumMember_zO3md8dfh5r4" title="Number of common stock shares issued">515,871 shares of its common stock to Mark L. Baum, its Chief Executive Officer, upon the vesting of <span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20210401__20210430__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--MarkLBaumMember_pii" title="Number of shares vested">850,000 performance-based restricted stock units. The Company withheld issuance of <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210401__20210430__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--MarkLBaumMember_pii" title="Number of common stock shares issued">334,129 shares of common stock valued at $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20210401__20210430__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--MarkLBaumMember_zqYaGn61wDxb" title="Value of shares issued">2,760 for payroll tax purposes. In April 2021, the Company issued <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210401__20210430__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--AndrewRBollMember_pii" title="Number of common stock shares issued">77,668 shares of common stock to Andrew R. Boll, its Chief Financial Officer, upon the vesting of <span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20210401__20210430__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--AndrewRBollMember_pii" title="Number of shares vested">127,500 performance-based restricted stock units. The Company withheld issuance of <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210401__20210430__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--AndrewRBollMember_pii" title="Number of common stock shares issued">49,832 shares of common stock valued at $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20210401__20210430__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--AndrewRBollMember_pn3n3" title="Value of shares issued">411 for payroll tax purposes. In April 2021, the Company issued 5,000 shares of its common stock upon the exercise of options to purchase <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210401__20210430__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_pii" title="Options to purchase shares of common stock">5,000 shares of common stock, with an exercise price of $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210401__20210430__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_pii" title="Exercise price per share">4.29 per share, and received net proceeds of $21. Sale of Eton Stock In April 2021, the Company closed the underwritten public offering of <span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pii_uShares_c20210401__20210430__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__custom--EtonStockSaleMember__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenPublicOfferingMember_zMM0VWEhWUga" title="Number of public offering shares issued">1,518,000 shares of its Eton common stock at a public offering price of $<span id="xdx_90E_eus-gaap--SaleOfStockPricePerShare_c20210430__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__custom--EtonStockSaleMember__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenPublicOfferingMember_pii" title="Offering price per share">7.00 per share (the “Eton Stock Sale”). The gross proceeds to the Company from the Eton Stock Sale were $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn3n3_c20210401__20210430__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__custom--EtonStockSaleMember__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenPublicOfferingMember_zm7YjQqX3nxg" title="Proceeds from offering">10,626, before deducting underwriting discounts and commissions and other offering expenses payable by the Company. Following such sale, the Company owns <span id="xdx_90B_eus-gaap--BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_pii_c20210401__20210430__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__custom--EtonStockSaleMember__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenPublicOfferingMember_zkDBKdognhal" title="Owned shares">1,982,000 shares of Eton common stock, which represented approximately <span id="xdx_90F_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pii_dp_uPure_c20210430__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__custom--EtonStockSaleMember__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenPublicOfferingMember_zrDf5N33zC0a" title="Equity voting interest percentage">8.1% of the equity and voting interests issued and outstanding of Eton as of April 12, 2021. As part of the Eton Stock Sale, the Company also agreed, for a period of 180 days, not to conduct any further sales of shares of its common stock of Eton or otherwise dispose of, directly or indirectly, any common stock of Eton (or any securities convertible into, or exercisable or exchangeable for, the common stock of Eton). 8.625% Senior Notes Due 2026 In April 2021, we closed an offering of $<span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_pip0_c20210430__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--EightPointSixTwentyFiveSeniorNotesDueTwentyTwentySixMember_ziJxo6BhRvXf" title="Debt principal amount">50,000 aggregate principal amount of <span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_uPure_c20210430__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--EightPointSixTwentyFiveSeniorNotesDueTwentyTwentySixMember_ze8iVuvf0qVi" title="Debt interest rate">8.625% Senior Notes due 2026 (the “Notes”) and in May 2021, the underwriters exercised their option to purchase an additional $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20210401__20210430__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--EightPointSixTwentyFiveSeniorNotesDueTwentyTwentySixMember__srt--TitleOfIndividualAxis__custom--UnderwritersMember_zem3UDTaoSbk" title="Value of shares issued">5,000 aggregate principal amount of the Notes ($<span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20210430__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--EightPointSixTwentyFiveSeniorNotesDueTwentyTwentySixMember__srt--TitleOfIndividualAxis__custom--UnderwritersMember_zSpFRsoRPz81" title="Debt principal amount">55,000 in total). The Notes are senior unsecured obligations of the Company and rank equally in right of payment with all of our other existing and future senior unsecured and unsubordinated indebtedness. The Notes are effectively subordinated in right of payment to all of the Company’s existing and future secured indebtedness and structurally subordinated to all existing and future indebtedness of the Company’s subsidiaries, including trade payables. The Notes bear interest at the rate of 8.625% per annum. Interest on the Notes is payable quarterly in arrears on January 31, April 30, July 31 and October 31 of each year, commencing on July 31, 2021. The Notes will mature on <span id="xdx_904_eus-gaap--DebtInstrumentMaturityDate_c20210401__20210430__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--EightPointSixTwentyFiveSeniorNotesDueTwentyTwentySixMember" title="Debt maturity date">April 30, 2026. Prior to February 1, 2026, the Company may, at its option, redeem the Notes, in whole at any time or in part from time to time, at a redemption price equal to <span id="xdx_903_eus-gaap--DebtInstrumentRedemptionPricePercentage_pii_dp_uPure_c20210401__20210430__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--EightPointSixTwentyFiveSeniorNotesDueTwentyTwentySixMember_z5KjTcdyzSrd" title="Debt redemption percentage">100% of the principal amount of the Notes to be redeemed, plus a make-whole amount, if any, plus accrued and unpaid interest to, but excluding, the date of redemption. The Company may redeem the Notes for cash in whole or in part at any time at our option on or after February 1, 2026 and prior to maturity, at a price equal to 100% of their principal amount, plus accrued and unpaid interest to, but excluding, the date of redemption. On and after any redemption date, interest will cease to accrue on the redeemed Notes. SWK Loan Repayment In April 2021, the Company paid $<span id="xdx_900_eus-gaap--RepaymentsOfRelatedPartyDebt_pn3n3_c20210401__20210430__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--SWKLoanMember_zRzCn2kE2Jv8" title="Repayment of loan">15,540 related to all outstanding obligations to SWK under the SWK Loan, including outstanding principal, accrued interest, accrued exit fee and related expenses. Series B Cumulative Preferred Stock In May 2021, the Company issued <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pii_c20210501__20210511__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBCumulativePreferredStockMember_zXtXKfsimy6j">440,000 shares of the Company’s Series B Cumulative Preferred Stock, par value $<span id="xdx_90D_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pii_c20210511__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBCumulativePreferredStockMember_zC1EVbatKDy1">0.001 per share and liquidation preference of $<span id="xdx_909_eus-gaap--PreferredStockLiquidationPreference_iI_pii_c20210511__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBCumulativePreferredStockMember_zkepDyDhwD2e">25.00 per share (the “Series B Preferred Stock”), for a net purchase price of approximately $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20210501__20210511__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBCumulativePreferredStockMember_z6CYGEy1Lqn7">10,670. The Series B Preferred Stock is not convertible into our common stock, has no voting rights, except as required by Delaware law, and is redeemable by the Company at any time. Holders of Series B Preferred Stock, when and as authorized by <span id="xdx_90B_eus-gaap--PreferredStockDividendPaymentTerms_c20210501__20210511__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBCumulativePreferredStockMember_zIibngNBvMwj" title="Preferred stock description">the Company’s Board of Directors, are entitled to cumulative cash dividends at the rate of <span id="xdx_90D_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20210501__20210511__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBCumulativePreferredStockMember_zXL0qJIBKCp" title="Preferred Stock, Dividend Rate, Percentage">9.50% of the $25.00 liquidation preference per year (equivalent to $2.375 per share per year); provided, however, that for each thirty (30) day period following May 5, 2021, the dividend rate shall be increased in increments of fifty (50) basis points, and effective September 30, 2021, the dividend rate shall be set at 12%, and for each thirty (30) day period thereafter, the dividend rate shall be increased in increments of one hundred (100) basis points except as otherwise limited by applicable law. Dividends will be payable quarterly in arrears, on or about the 15th of January, April, July and October, beginning on or about July 15, 2021. In the event of any liquidation, dissolution or winding-up of the Company, the holders of the Series B Preferred Stock will have preference to holders of our common stock at $<span id="xdx_90C_eus-gaap--SharePrice_iI_pid_c20210511__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--EllePharmaceuticalLLCMember_zfklyr4QCuBd" title="Share price per share">25.00 per share plus any accrued and unpaid dividends (whether or not authorized or declared). Mayfield Pharmaceuticals MAY-66 License Termination In May 2021, Mayfield terminated the License Agreement (the “TGV License”) with TGV-Health, LLC and affiliated entities (collectively, “TGV”), pursuant to which it acquired intellectual property rights for use in the women’s health field, related to Mayfield’s proprietary drug candidate MAY-66. Concurrent with the termination, TGV returned to Mayfield <span id="xdx_90A_eus-gaap--StockRepurchasedDuringPeriodShares_pii_c20210501__20210511__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--BusinessAcquisitionAxis__custom--TGVHealthLLCMember_zI2USEEb24yi" title="Number of shares returned">300,000 shares of Mayfield’s common stock, constituting all of the equity held by TGV. Mayfield has no outstanding or remaining obligations under the TGV License. Mayfield Pharmaceuticals MAY-44 APA Termination In May 2021, Mayfield and Harrow terminated their asset purchase agreement dated January 2020 for intellectual property rights associated with Mayfield’s drug candidate MAY-44 with Elle Pharmaceutical LLC (the “MAY-44 APA”). As part of the termination, Mayfield re-acquired <span id="xdx_906_eus-gaap--StockRepurchasedDuringPeriodShares_pii_c20210501__20210511__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--BusinessAcquisitionAxis__custom--EllePharmaceuticalLLCMember_zFdUobYilDX5" title="Number of shares returned">350,000 shares of its common stock from Elle. Mayfield has no outstanding or remaining obligations related to the MAY-44 APA. Stowe License Termination In May 2021, Stowe terminated the License Agreement (the “Stowe License”) with TGV, pursuant to which it acquired intellectual property rights for use in the ophthalmic field, related to Stowe’s proprietary drug candidate STE-006. Concurrent with the termination, TGV returned to Stowe <span id="xdx_909_eus-gaap--StockRepurchasedDuringPeriodShares_pii_c20210501__20210511__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--BusinessAcquisitionAxis__custom--StowePharmaceuticalsIncMember_zpw0PLFvQXL2" title="Number of shares returned">1,750,000 shares of Stowe’s common stock, constituting all of the equity held by TGV. Stowe has no outstanding or remaining obligations under the Stowe License.

515871

850000

334129

2760000

77668

127500

49832

411000

5000

4.29

21000

1518000

7.00

10626000

1982000

0.081

50000

0.08625

5000

55000

2026-04-30

15540000

440000

0.001

25.00

10670000

the Company’s Board of Directors, are entitled to cumulative cash dividends at the rate of 9.50% of the $25.00 liquidation preference per year (equivalent to $2.375 per share per year); provided, however, that for each thirty (30) day period following May 5, 2021, the dividend rate shall be increased in increments of fifty (50) basis points, and effective September 30, 2021, the dividend rate shall be set at 12%, and for each thirty (30) day period thereafter, the dividend rate shall be increased in increments of one hundred (100) basis points except as otherwise limited by applicable law. Dividends will be payable quarterly in arrears, on or about the 15th of January, April, July and October, beginning on or about July 15, 2021.

0.0950

25.00

300000

350000

1750000